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Abstract 
Recent years have seen an upsurge in interest in the relationship between helminth infections 
and metabolic diseases such as insulin resistance and type 2 diabetes mellitus (T2DM). 
Limited clinical and laboratory studies have suggested that chronic helminth infections may 
protect against the development of T2DM, and have suggested an immunometabolic 
mechanism for such an effect. 
Aims 
This thesis seeks to examine the relationship between Strongyloides stercoralis infection and 
T2DM in an Australian Aboriginal community, and to examine the importance of this 
relationship in the context of efforts to treat and control this infection.  
  
 vi 
Methods 
The thesis reports on a cross sectional observational study of adults attending the health 
centres in an Aboriginal community, testing them for both strongyloides infection and 
T2DM, and establishing the nature of the relationship between these two conditions. A cohort 
of infected and un-infected subjects is thereby established and followed over a three-year 
period, enabling characterization of both the treatment outcomes for this infection at 6 
months and three years in the context of T2DM, and the effects that treatment for 
strongyloides has on subsequent metabolic parameters. In addition, the relationship between 
S. stercoralis infection, T2DM and eosinophilia is examined, and limited studies into the 
cytokine responses in treated individuals are performed 
Results 
The study demonstrates a strong negative association between pre-existing S. stercoralis 
infection and T2DM. It shows T2DM is a predictor of treatment failure for S. stercoralis at 6 
months, and demonstrates that eosinophilia is not a reliable predictor of S stercoralis 
infection in this community, but is a more constant finding in those patients with  
S. stercoralis and T2DM. The three-year follow up shows that ivermectin is an extremely 
effective treatment for S. stercoralis infection in this community, and demonstrates that 
treatment of S. stercoralis infection is associated with an increased risk of developing T2DM 
and impaired glucose tolerance when compared to an uninfected and untreated group. 
Conclusions 
The thesis provides evidence to support a protective effect for S. stercoralis infection against 
T2DM and suggests an immunometabolic model to explain the negative association which 
has been found. These findings are discussed in the context of ongoing efforts to control and 
eliminate strongyloides infection in Australian Aboriginal communities. 
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Chapter 1 Helminth Infection and Metabolic Disease in Humans: 
an Introduction and Literature Review 
1.1 Helminth Infection and Type 2 Diabetes Mellitus 
 
Recent years have seen an upsurge in interest in the relationship between helminth infections 
and metabolic diseases such as insulin resistance and type 2 diabetes mellitus (T2DM) - two 
areas of medicine that may have previously seemed distant from each other both in 
geographical and pathophysiological terms. Whilst both conditions are common in a global 
sense, their regions of greatest prevalence have traditionally had little overlap, with helminth 
infections common in the developing world, and T2DM most prevalent in the developed 
world. Past decades have however, seen an epidemic of metabolic disease and T2DM in 
“transitional” societies (those undergoing the change from “developing” to “developed”) 
where helminth infections have been common in the past.  
The “hygiene hypothesis”, current since the 1980’s, has postulated that the relatively low 
levels of allergic and autoimmune diseases seen in some developing societies may reflect the 
high levels of infectious diseases there, through modulation of the immune system by early 
exposure to these conditions1, 2. The apparent inverse relationship between parasitic diseases 
such as helminth infections, and metabolic disease can therefore be seen by analogy as an 
extension of this theory. 
The world is currently experiencing an epidemic of Type 2 diabetes mellitus and its 
consequences. It is estimated that the total number of people living with T2DM will exceed 
366 million by 20303. This is occurring not just in the developed world, but also to an 
increasingly greater extent in the developing world, where it was until recently an uncommon 
condition. In China for example, the national prevalence of T2DM was 11.6% in 2010 
compared with 5% in 2001 and 1% in 19803.  Diabetes in the developing world is more 
commonly poorly controlled and it is being observed in progressively younger populations. It 
is more likely to remain undiagnosed, or to be treated inadequately. This is also the case for 
relatively underprivileged populations living within developed societies, in particular the 
indigenous populations in North America and Australia4. 
 In addition to T2DM, the antecedent conditions that constitute the metabolic syndrome, such 
as obesity, dyslipidemia, hypertension and insulin resistance, are also increasing in 
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prevalence. It is a commonplace to attribute these increases to the adoption of “Western” 
diets with the effects of excessive nutrition and high fat diets being well documented. 
However, changes in diet are not the only demographic and environmental changes observed 
in such transitional societies, with increasing urbanization, changes in patterns of physical 
activity, standards of hygiene and patterns of infectious diseases all being evident. It is 
therefore plausible that these factors could also influence the prevalence of T2DM.  
An improved understanding of the immunology underlying helminth infections and their 
ability to modulate the human immune system, and an improved understanding of the 
relationship of T2DM and metabolic disease to inflammation have prompted further interest 
in this relationship.  
Helminths are known to be master manipulators of the host immune system, capable of 
inducing modified T helper cell type 2 (Th2) weighted immune responses which have the 
dual effect of reducing harmful inflammation in the host, while ensuring the parasites’ 
survival5. At the same time, T2DM is increasingly seen as a disease of chronic inflammation, 
with inflammation in adipose tissue in particular both a cause and consequence of insulin 
resistance in peripheral tissues, and ultimately T2DM and its metabolic consequences6, 7. 
Seminal research conducted in the early years of this decade has established a link between 
helminth infections, subsequent eosinophilia and Th2 weighted immune responses, and the 
molecular pathways that regulate glucose metabolism and insulin sensitivity8, 9. This 
laboratory work preceded clinical and observational studies in this field and had the effect of 
prompting a number of studies, including the current one, into this phenomenon.  
Questions regarding the relationship between helminth infection and metabolic disease have 
far more interest than matters of academic interest, and clearly may be of importance in 
decisions of a public health nature in both developing and transitional societies. In addition to 
the decline in helminth infections that is an inevitable consequence of improved levels of 
hygiene and housing, there are well-developed WHO public health programs that aim to 
reduce and eliminate these conditions worldwide. Examples include programs to eradicate 
onchocerciasis, lymphatic filariasis and schistosomiasis, which have met with considerable 
success in reducing the public health impact of these damaging conditions. WHO sponsored 
programs to reduce the impact of soil-transmitted helminth (STH) infections have met with 
more questionable success, and the health benefits of such programs have been brought into 
question10, 11. Should the link between metabolic disease and helminth infection be more 
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firmly established, then these public health interventions and their consequences clearly face 
further questions in the context of societies that already face an epidemic of metabolic and 
non-communicable diseases in the coming decades. 
1.1.1 Strongyloides stercoralis 
Strongyloides stercoralis is a soil transmitted helminth (STH) infection affecting mostly poor 
societies in tropical and temperate climates worldwide, and is recognized as one of the WHO 
neglected tropical diseases. Estimates of its prevalence have depended on mainly incomplete 
epidemiological data, and have usually been stated as 70 to 100 million cases. More recent 
estimates have revised this up to 370 million12. The infection was first identified in the 1800s 
and much work on its life cycle and transmission was completed in the early 20th century13. 
As hygiene and living conditions improved in the developed world through the second half of 
the 20th century, the infection became increasingly uncommon, and it is now rare in 
developed societies. It remains common in developing and transitional societies, and in 
certain under-privileged groups living within developed societies14.  
1.1.1.1 Lifecycle 
The widespread distribution of this infection, and the nature of its transmission and 
pathophysiology make it an ideal candidate to study in the context of metabolic disease. To 
understand this, it is necessary to understand some key points regarding the life cycle, 
transmission and clinical effects of the infection, as these are central to understanding its 
ability to produce chronic disease13, 15. As with hookworm species, infection occurs when the 
infective larvae, present in faeces or in contaminated soil, penetrate the host’s skin. The 
larvae migrate through the bloodstream and body fluids of the host to the lungs, where a 
series of developmental stages occur before the larvae finally migrate to the intestine of the 
host, and adult female worms are established in the sub-mucosal layer. 
These female worms produce eggs by parthenogenesis, which then hatch into larvae whilst in 
the intestine. “Rhabditiform” larvae are passed in the faeces and one of two external life 
cycles is completed. The rhabditiform larvae can complete a number of moltings to produce 
infective, filariform (L3) larvae and then re-infect a new host. Alternately these larvae may 
develop into externally living adult male and female pairs, which then produce larvae by 
sexual reproduction. The disposition of rhabditiform larvae to one of these two outcomes is 
incompletely understood and is thought to depend upon both internal factors, such as the 
host’s immune response, and external factors such as temperature and moisture16. 
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A crucial point of difference in the lifecycle of S. stercoralis when compared to other STH is 
that rhabditiform larvae can complete the transition to infective larvae whilst within the 
host’s intestine, and these “auto-infective” larvae can then penetrate the bowel wall, or the 
skin of the anal margin, thus completing an internal re-infection cycle. In this way  
S. stercoralis differs from all other STH infections in that chronic infections can be 
established in the absence of ongoing environmental exposure to the larvae. This enables the 
establishment of “life-long” systemic infections both in individuals living in endemic 
communities, and in those who have migrated from endemic to non-endemic regions. The 
continuing presence of the worm in the superficial layers of the intestinal wall, and the 
intermittent penetration of the bowel wall by larvae which then migrate through the hosts 
body, will also presumably provide a more constant and sustained stimulus to the host’s 
immune system than an infection which is confined to the lumen of the bowel and where the 
life cycle of the worm relies on entirely external mechanisms and repeated re-exposure to the 
eggs or larvae, as is the case in other STH infections. 
The worm’s ability to sustain chronic infections in its host also means that human beings are 
the likely principal reservoir of infection in endemic societies, although recent work also 
suggests that dogs may constitute an additional reservoir of infection17. Infective L3 larvae 
produced via parthenogenesis are thought to survive only about 14 days in the external 
environment, presumably under favorable conditions18. The L3 larvae that arise from the 
external sexual reproductive cycle may survive for longer periods, perhaps even indefinitely, 
but there is only ever one generation of free living adult worms, and the relative contribution 
of the external and internal reproductive cycles is likely to depend on numerous external and 
host factors16. The location of the reservoir of infection is of importance from a practical 
point of view. If the reservoir is principally, or effectively entirely within the human 
population, then the infection lends itself to elimination via pharmacological means such as 
“case finding and treatment” and/or mass drug administration (MDA). If the environment 
constitutes a significant reservoir, then environmental manipulation will be crucial to the 
control of the infection. 
1.1.1.2 A “neglected” neglected tropical disease 
Further reasons for the relative neglect of strongyloides infection stem from peculiarities in 
the symptoms and disease burden produced by S. stercoralis infection, and the means 
available for diagnosis and treatment14. 
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While S. stercoralis is a common infection worldwide, the burden of disease that it produces 
remains less certain. Early descriptions of the disease describe it as a cause of diarrhea and 
gastrointestinal symptoms13. The classic description of the disease in western society was in 
returned prisoners of war, where high rates of itchiness, rash and gastrointestinal symptoms 
were reported19, 20. This included the pathognomonic creeping eruption “Larvae currens” 
produced by migration of larvae through the host’s skin. 
In practice, these manifestations seem to be less common in endemic societies where the 
presence of more longstanding infections may result in fewer symptoms15, and where 
conceivably, the mild or irritating symptoms produced are obscured by the more pressing 
presence of other infectious diseases. A study conducted in Africa described higher 
incidences of self-reported “general ill health”, gastrointestinal disturbances and cough with 
wheeze, in subjects with S. stercoralis, but still the majority of those infected reported no 
symptoms21. The absence of association with more clinically damaging conditions seen in 
other STH infections, such as maternal and childhood anaemia and failure to thrive, has led to 
the relative neglect of S. stercoralis.  
The principal clinical complication of S. stercoralis infection in developed societies is that of 
hyper-infection syndrome22. Hyper-infection occurs most frequently in circumstances where 
the host’s immunity becomes impaired in the presence of an acute or chronic S. stercoralis 
infection. The adult worms in the bowel begin to produce auto-infective larvae in huge 
numbers and these penetrate the host’s body, carrying with them gram negative and other 
bacteria, and resulting in widespread infections and septicemia. Established cases are often 
misdiagnosed, are difficult to treat, and have a high mortality rate. This syndrome is most 
commonly a consequence of the administration of steroids or other immunosuppressant 
drugs, or in co-infections with the retrovirus HTLV-1, but has also been reported as a 
complication of HIV infection, alcoholism, haematological and solid malignancy, and a 
variety of other conditions. Infrequently it may occur in the absence of any known 
precipitating factor. Although it undoubtedly occurs in developing societies, it most likely 
often goes unrecognized, and its iatrogenic causes are more frequently encountered in the 
developed world. It is therefore a significant risk for those migrating from endemic to non-
endemic societies, or those living in at-risk populations within developed societies. 
Difficulties with the diagnosis of S. stercoralis have in the past lead to underestimates of its 
prevalence, and contributed to its relative neglect in comparison to other STH infections23. 
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S. stercoralis eggs are not passed in the faeces and so conventional and relatively simple 
parasitological investigations used for the detection of other STH infections, such as the 
Kato-Katz method are unlikely to detect the infection. Specialized techniques for detecting 
the larvae such as the Baermann funnel method, the Harada-Mori filter paper system, and 
Kogar agar plate culture have been developed, and have improved sensitivity24. These 
methods are however, time and labor intensive, rely on the collection of large and multiple 
faecal specimens, and are dependent on experienced and readily available laboratory staff. In 
practice, this makes such investigation difficult, and often impractical in endemic societies. 
While the tests are specific in experienced hands, their sensitivity is low even under ideal 
circumstances. 
The poor performance of direct methods of diagnosis has led to the development of various 
other means of diagnosis for S. stercoralis, including immunological tests and molecular 
diagnosis, however, questions remain over the sensitivity and specificity of these methods. 
Determination of sensitivity and specificity of indirect diagnostic tests is rendered more 
difficult by the absence of a “gold standard” diagnostic test with which to compare. Recent 
studies have looked at the performance of indirect tests in the diagnosis, and follow up of 
 S. stercoralis and have included commercially produced ELISA tests detecting IgG 
antibodies25, 26. They have concluded that these tests are sensitive and specific enough to be 
of use in the diagnosis and follow up of treatment for S. stercoralis infection, however, 
questions still remain over the cut-off point used for diagnosis of infection in endemic 
societies, and the definition of treatment success in relation to antibody changes after 
treatment.  
Other advances in diagnosis include the development of faecal PCR tests for the detection of 
worm DNA in faeces. These tests promise improved sensitivity and are less “operator 
dependent”, but still rely upon the presence of larval shedding in the faeces, which is known 
to be only intermittent and light in chronic infections24. A recent study suggested that faecal 
PCR was superior to direct examination in its sensitivity, but that both tests, either alone or in 
combination, were still less sensitive than serology27. Clearly the development of a rapid, on 
site detection method with adequate sensitivity and specificity would contribute to the 
understanding and treatment of this infection. 
Treatment for S. stercoralis also differs from the treatment for other STH infections, and has 
thus contributed to its exclusion when consideration is given to worm control programs23. 
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Albendazole, which is the standard treatment for all other STH infections, is known to be 
relatively ineffective against S. stercoralis, even when given in relatively prolonged courses2, 
28. Ivermectin is now considered to be the treatment of choice, although questions still exist 
with regard to the best dosing regimen. Other anthelminthic drugs such as thiabendazole have 
been shown to be equally effective, but have a higher side effect profile29. Recently another 
drug from the avermectin group, moxidectin, has been shown to be effective30. 
1.1.1.3 Strongyloides infection in Australia 
The situation with regard to strongyloides infection in Australia to some extent reflects that 
which exists in the wider world.  The overall prevalence of S. stercoralis infection in non-
Aboriginal Australia is low, in keeping with its status as a developed country, with the 
exception of some immigrant and refugee populations originating from endemic regions. This 
is not the case however, in Aboriginal communities in the north of the country where health 
and hygiene conditions more closely resemble those seen in transitional and developing 
societies. Although epidemiological data are incomplete, prevalence of up to 60% has been 
reported in some studies31, and attempts are currently underway to improve upon the quality 
and range of data available, raise awareness of the condition and systematize the 
investigation and treatment of those in affected communities32. The health impact of  
S. stercoralis infection is largely unknown, although hyper-infection and severe 
strongyloidiasis is a recognized problem in central Australia, and may be compounded by the 
presence of HTLV-1 infection, which is a known predisposing factor for this condition33. 
Data are lacking on the effectiveness of ivermectin treatment in the setting of Aboriginal 
communities, and on the effectiveness of attempts to control or eliminate the infection 
through pharmacological means34.  
1.1.2 Type 2 diabetes mellitus and inflammation 
The link between obesity, the metabolic syndrome, T2DM and inflammation is now well 
established. As the role of inflammation and the immune response in T2DM and insulin 
resistance is central to this thesis it is necessary to review the main body of knowledge in this 
regard. 
The first recognition of a role for inflammation in obesity and insulin resistance came 25 
years ago with the discovery that levels of the pro-inflammatory cytokine TNF- were 
elevated in the adipose tissue of obese individuals35. Since that time, the role of adipose tissue 
as an endocrine organ has been revealed, with its production of numerous pro and  
 8 
anti-inflammatory cytokines such as IL-1, IL-6, TNF- and Il-10, along with adipokines such 
as leptin and adiponectin. Subsequently it was revealed that, although adipocytes are 
responsible for the secretion of some of these cytokines, tissue macrophages within adipose 
tissue constitute the major source of cytokine production36.  
The adipose tissue of obese individuals is known to be an inflammatory environment, with 
necrosis of adipocytes attracting type 1 or “classically activated” macrophages, associated 
with the production of pro-inflammatory cytokines. This necrosis and inflammation is 
thought to be attributable to excessive nutrition and rapid expansion of adipose tissue, 
resulting in relative hypoxia and poor blood flow and adipocyte death, as well as the direct 
effects of high levels of free fatty acids. By contrast, the adipose tissue of lean individuals is a 
relatively anti-inflammatory environment with type 2 or “alternatively activated 
“macrophages (AAM) distributed throughout the tissue, responsible for the production of 
anti-inflammatory cytokines such as IL-10.  
The presence of either type 1 or type 2 macrophages, and the cytokines they produce then has 
direct consequences for glucose metabolism and insulin sensitivity, with pro-inflammatory 
cytokines reducing the sensitivity to insulin of adipose tissue and other effector organs such 
as liver and skeletal muscle, while anti-inflammatory cytokines have the opposite effects.  
Recruitment of alternatively activated macrophages to adipose tissue is central to maintaining 
energy homeostasis and occurs via an IL-4 dependent pathway. AAMs not only produce anti-
inflammatory cytokines such as IL-10, but they act to down-regulate classically activated 
macrophages, and are necessary for the development and sustaining of healthy adipose tissue. 
In addition, cells of the adaptive immune system are involved in the ongoing maintenance of 
an anti-inflammatory environment, with a reduction in the number of Th1 weighted T cells, 
and an increase in the proportion of T reg cells9. 
Recent work has concluded that eosinophilic infiltration of adipose tissue is the strongest 
stimulus for producing and sustaining AAMs in these tissues. This was supported by the 
establishment of experimental helminth infections in mice producing tissue eosinophilia that 
then sustained AAMs in adipose tissue, and produced an improvement in insulin sensitivity8.  
It is possible therefore to propose a model based on adaptions to survive different infections 
that could connect the immunological states in individuals, and their differing effects on 
glucose metabolism9. Acute bacterial and viral infections, which pose an immediate 
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existential threat to the organism, are met with a prompt and often massive immune response, 
with mobilization of large populations of cells from the innate and adaptive immune systems. 
This is associated with a Th1 weighted immune reaction, involving the production of pro-
inflammatory cytokines such as TNF-, IL-6 and Il-1, and these cytokines have the effect 
of reducing insulin sensitivity, impairing the peripheral storage of nutrients and promoting 
gluconeogenesis in the liver, thereby ensuring the ready availability of substrate for the 
immune cells produced in response to infection. Thus, reduced insulin sensitivity and relative 
hyperglycemia is an adaptive response to enhance survival during acute life-threatening 
infections.  
Conversely, infections with parasites rarely constitute a sudden existential threat to the host. 
Rather, the threat to the host comes more through a long-term impost on nutritional 
resources, and potentially, the effects of excessive and prolonged inflammatory reactions in 
response to the continuing presence of parasite antigens. Parasite infections are associated 
with Th2 weighted immune responses, with the production of Il-4 and IL-13, recruitment of 
eosinophils and AAMs to affected tissues and the production of anti-inflammatory cytokines 
such as IL-10 and IL-1RA. These have the effect of increasing insulin sensitivity in 
peripheral tissues, which enhances the storage and efficient use of nutrients, and has the dual 
effect of reducing the availability of nutrients for the pathogen, thereby reducing its potential 
for survival and growth, while conserving resources for the host and thereby improving its 
chances of survival in the face of long-term infection. The damping down of the host 
inflammatory response also has the effect of reducing the potential damage inflicted on host 
tissues by longstanding inflammation9.  
1.1.3 A model for the immune-metabolic effect of infection 
It is not difficult therefore to conceive of a circumstance where the dysregulation of the 
inflammatory response to recurrent bacterial and viral infections could lead to a prolonged 
reduction in insulin sensitivity, hyperglycaemia and subsequent T2DM. Similarly, prolonged 
exposure to parasitic infections could result in a persistent modified Th2 weighted 
inflammatory environment, with recruitment of AAM’s to adipose tissue, and subsequent 
enhanced insulin sensitivity and a reduced incidence of T2DM.  
For subjects living in transitional societies, such as the Aboriginal people who are the subject 
of this thesis, there may therefore be more than one pathway to insulin resistance and T2DM. 
In Australian Aboriginal populations, there is clear evidence for increasing rates of obesity 
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and T2DM over a period of decades37, 38. While the developed world has seen the 
simultaneous advent of over-nutrition and the reduction of infections of all kinds through 
improved hygiene, only a part of this transition has been achieved in Aboriginal societies. 
Food security, and indeed over-nutrition may have generally become more established, but 
infections of all kinds, particularly bacterial skin infection, chronic otitis media, recurrent 
upper and lower respiratory tract infection, bronchiectasis, and periodontal and dental disease 
are all still extremely frequent in these societies. On the other hand, efforts to control and 
eliminate some parasitic infections have met with greater success, with improvements in 
housing and the widespread use of albendazole in public health programs leading to a marked 
and progressive reduction in the prevalence of hookworm infection in the same 
communities39, 40. The relative roles of inflammation from infectious causes, and 
inflammation from the effects of obesity and over nutrition, and the mitigating effects of 
parasitic infection in the pathogenesis of T2DM in these populations, is a topic that has 
received little attention. Clearly, understanding the complex of factors in play may be of 
importance to the means employed to both treat and prevent T2DM in these communities.  
Alternate explanations may also be proposed to explain the prevalence of diabetes in 
Aboriginal populations. The role of the gut biota in metabolic disease is being seen as 
increasingly important. Subjects with T2DM are known to sustain a different gut flora to non-
diabetics41 and this may responsible for maintaining a more pro-inflammatory environment 
within the body generally. Repeated doses of antibiotics in response to recurrent bacterial 
infections that characterize the early life of many indigenous children, could lead to a 
permanent change in the gut flora. Furthermore it is known that the presence of helminth 
infection itself can affect the gut biota42. 
Genetic predispositions to T2DM, such as the role played by genetic polymorphisms in the 
expression of cytokines, clearly may also be of importance in Aboriginal populations. For 
example, studies in the investigation of Sudden Infant Death syndrome seem to indicate that 
Aboriginal populations may carry genes expressing lower levels of IL-1043 and higher levels 
of pro-inflammatory cytokines, but this has not been investigated in the context of T2DM.  
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1.2 Clinical Studies into the Relationship between T2DM, Metabolic Disease 
and Helminth Infections- a Review of the Literature 
Over the past 7 years a number of clinical studies have appeared which examine the 
relationship between T2DM and helminth infections. These studies have examined helminth 
infections both as an outcome, and as a determinant of T2DM. In addition, one prospective 
trial of treatment for helminth infection and its effect on glucose metabolism was conducted 
and reported on during the course of this thesis project44. A number of studies have looked at 
helminth infections in relation to other complications of the metabolic syndrome such as 
atherosclerosis, atherogenic index and cardiovascular disease. Following on from these 
studies, there has been one meta-analysis examining the relationship between T2DM and 
helminth infection, and numerous review articles examining these topics. 
1.2.1 Search strategy 
The strategy adopted for this review employed a search of MEDLINE and EMBASE data 
bases. It was restricted to human studies with abstracts in English, and searched for research 
articles, review articles, meta-analyses and systematic reviews, conference abstracts, 
editorials and letters. The papers which constitute the subject matter of this thesis were not 
included. 768 abstracts were retrieved using this search strategy, and the titles were 
manually scanned for relevance. A total of 67 studies were identified and had their 
abstracts reviewed. The references in all review articles were also examined for 
relevant papers. This resulted in the inclusion of a total of 38 publications (15 research 
articles, 18 review articles, 1 meta-analysis and 4 others). The search strategy employed 
and a full list of the references identified is presented in Appendix 1. 
1.2.2 Helminth infection and T2DM 
To date, cross sectional observational studies that examine the relationship between helminth 
infection and T2DM and the metabolic syndrome, have found a negative association. The 
first study to report upon a relationship between diabetes and helminth infection was an 
observational study from Turkey45. The investigators here were concerned with soil 
transmitted helminth infection as an outcome and included patients with both T1DM and 
T2DM in the survey. To the author’s surprise they discovered a negative association, with 
47% of diabetic patients testing positive, compared to 55% of 1024 controls (p<0.05). They 
explained the reduced prevalence by the increased surveillance that diabetic patients receive 
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from their primary care practitioners, and did not consider the possibility of a protective 
effect from helminth infection. 
The first such study to consider this possibility appeared in 2010, although the authors again 
designed the study with diabetes as the exposure and filarial infection as the outcome. 
Aravindhan et. al examined the prevalence of lymphatic filariasis (LF) among diabetic 
subjects, as part of the CURES (Chennai Urban Rural Epidemiology Study) in southern 
India46. 1416 subjects were tested, and statistically significant lower rates of LF sero-
positivity were found in those with existing diabetes (4.3%) and newly diagnosed diabetes 
(5.7%), when compared to those with pre-diabetes (9.1%) and non-diabetics (10.4%). While 
the relationship held when adjusted for age, sex and socio-economic status, no adjustment 
was made for differences in BMI, even though BMI was significantly higher in diabetic 
groups compared to non-diabetic. This study also examined the level of circulating filarial 
antigen, which was lower among diabetics, and the levels of selected pro-inflammatory and 
anti-inflammatory cytokines. Those with positive filarial antigen had lower levels of the pro-
inflammatory cytokines TNF-, IL-6, and GM-CSF. No difference was present in the levels 
of anti-inflammatory cytokines. The authors suggest that the observed lower incidence of 
T2DM could be related to an amelioration of the pro-inflammatory environment associated 
with T2DM. 
A study published in 2013 reported on the relationship between past schistosomiasis and 
T2DM in a rural Chinese population47. A self-reported history of schistosomiasis, validated 
by government records, and a number parameters measuring T2DM and insulin resistance 
were measured in 3913 subjects over the age of 60. There was a negative association between 
past infection and all the metabolic parameters measured, and this relationship persisted when 
adjusted for numerous demographic and anthropometric factors such as sex, age, BMI and 
diet. Another study conducted in China looked at past schistosome infection and the 
components of the metabolic syndrome, including central obesity, triglyceride levels, total 
cholesterol, HDL, LDL, plasma glucose levels and blood pressure, in a region where S. 
japonicum infection had historically been prevalent48. They examined 1132 subjects, 465 of 
whom had past schistosome infection and found a negative relationship to all components of 
the metabolic syndrome tested, although the statistical relevance of the relationship with 
blood glucose levels was reduced under multivariate analysis. 
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In 2015 Wiria et.al. tested 646 adults in Indonesia for a relationship between Soil Transmitted 
Helminth (STH) infection and insulin sensitivity49. Subjects were tested for A. lumbricoides, 
T. trichuria, A. duodenale, N. americanus and S. strongyloides and their insulin levels and 
homeostatic model assessment for insulin resistance (HOMA-IR) were calculated. A 
significant reduction in HOMA-IR, mostly attributable to lower insulin levels, was found in 
infected subjects. The relationship was found to correlate with the number of infections 
present, and it remained significant when adjusted for BMI. 
The same group of researchers in Indonesia announced the first prospective trial to examine 
the effect of treatment for helminth infection on insulin resistance in 2016. The 
“SUGARSPIN” trial was a household based, double blind, cluster-randomized trial of 
treatment with albendazole for STH infection and its effect on insulin resistance in a 
population on Flores island Indonesia, where STH infection was common.  Results of this 
study were published in 201750 and failed to show an effect of albendazole treatment on 
insulin resistance (IR) at a community level. However, when only those who were found to 
be infected with helminths were included, a significant effect on HOMA-IR was recorded 
(increase in IR 0.031, confidence interval 0.004-0.059, p=0.04). The authors note that the 
treatment effect on IR was only moderate, and that it was attenuated by adjustment for 
changes in BMI. They speculate that this, and the absence of effect at a community level, 
could be due to the relatively short period of follow up, and the possibility that past infections 
with helminths were exerting an ongoing effect on IR, as has been suggested by past 
observational studies. It should also be noted that S. stercoralis infection in this community 
was measured as less than 1% by faecal PCR testing and appeared to disappear entirely after 
albendazole treatment. Faecal PCR testing for strongyloides, while more sensitive than direct 
parasitological tests, may still have low and variable sensitivity on single specimens27. 
Studies elsewhere suggest that short courses of albendazole are likely to be ineffective as a 
treatment for strongyloides2, 28. If the study failed to accurately diagnose S. stercoralis 
infection, or indeed infection with any other helminths, then this would have the effect of 
diluting any observed effect and may partially account for the absence of any observed effect 
at a community level. Nevertheless, this study represents the first prospective study of its 
kind, and seems to confirm the hypothesis that treatment of STH may have an effect on IR. 
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1.2.3 Helminth infections and other metabolic outcomes 
In addition to studies that look directly at T2DM and the metabolic syndrome, there have 
been several which look at further outcomes, in particular the atherogenic index, the presence 
of atherosclerosis, and the rate of cardiovascular disease. In general, these studies have found 
a less constant relationship with helminth infection. 
Aravindhan and the CURES study examined the relationship between LF infection and 
coronary artery disease in 453 subjects and found no relationship51. They further found no 
relationship with intimal medial thickness and serum CRP levels in the same group, and no 
evidence of protective immunomodulation. 
An Indonesian study looked at STH infection and a range of atherogenic indicators along 
with carotid intimal medial thickness52. They found a negative effect of helminth infection on 
CVD risk factors such as total cholesterol, BMI and waist/hip ratio, but no relationship to 
carotid intimal medial thickness. 
In contrast, a Russian study examined the relationship between chronic infection with the 
liver helminth Opisthorchis felineus and aortic atherosclerosis in autopsy specimens53.  Three 
hundred and nineteen cadavers were examined and a linear negative association described 
between worm burden and both atherosclerosis and total cholesterol levels. Interestingly, data 
with regard to T2DM were recorded as part of the study, but did not show any relationship to 
worm infection or burden. This may have been partly due to the preponderance of young, 
otherwise fit, males in this autopsy study. 
A Chinese study of 1597 men aged over 45 years found a significant reduction in the 
atherogenic index of plasma (AIP), triglycerides, waist circumference and body mass index 
for those with a history of past schistosomiasis compared to controls54. The relationship to the 
AIP persisted when adjusted for BMI and waist circumference, suggesting that past 
schistosomiasis was an independent risk factor. 
In 2017 the SUGARSPIN group reported on the outcome of treatment for helminth infections 
with albendazole, and the adipokines leptin, adiponectin and resistin55. These metabolically 
active hormones are thought to be involved in the regulation of metabolism and insulin 
sensitivity, and resistin levels have been implicated in the outcome of treatment for helminth 
infections56. Adiponectin is known to be associated with improved insulin sensitivity, while 
leptin and resistin are thought to be associated with increased insulin resistance. The study 
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showed a significant increase in the ratio of leptin to adiponectin (treatment effect factor 
(95% confidence interval), P-value for interaction: 1.20 (1.06-1.35), P=0.010), due largely to 
an decrease in adiponectin levels, in helminth infected individuals after treatment with 
albendazole. The effect was thought to account, at least in part, for the effect on insulin 
sensitivity seen in their earlier study. No effect was demonstrated in resistin levels. 
1.2.4 Strongyloides and T2DM 
Prior to the studies constituting the subject of this thesis there was little in the literature in 
regard to T2DM and Strongyloides stercoralis.  
A study in India in 2011 examined the risk factors for Strongyloides stercoralis infection in a 
hospital population57. It was a retrospective study employing case record reviews, and looked 
at S. stercoralis infection as an outcome. Its principal concern was with HIV infection, but it 
does record T2DM as a potential risk factor. Although there were only 22 T2DM patients out 
of 358 subjects, a statistically significant negative association (OR 0.19, CI 0.04-0.83) with 
strongyloides infection goes uncommented upon in the study. 
The only paper to report upon a positive relationship between helminth infection and T2DM 
was a small observational study conducted in a Brazilian endocrinology clinic in 200658. 78 
diabetic patients were compared to 42 controls with other endocrinological conditions, and a 
positive association with S. stercoralis infection was described (OR 3.9, CI 1.6-15.9). In 
addition, diabetic patients with a lower HbA1c were found to be less likely to have  
S. stercoralis infection. This study is notable as it stands alone as the only study to find a 
positive association between helminth infection and T2DM, and the reason for this, 
apparently contrary, finding is not immediately clear. The study relies on the presence of 
current infection in a region described as “hyper-endemic” for S. stercoralis infection, and no 
history of past anthelminthic treatment is given. Therefore, it is not known whether the 
subjects have recent infection, longstanding infection, or indeed both. A protective effect for 
S. stercoralis would presumably not be expected to manifest itself if the majority of 
infections were recently contracted, or in older patients who already had T2DM. 
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1.3 Thesis Outline 
This thesis seeks to examine the relationship between Strongyloides stercoralis infection and 
T2DM in an Australian Aboriginal community. It postulates that a negative relationship will 
be found between the two conditions, and that evidence will be found in support of an 
immunometabolic mechanism to explain this finding. In addition, the thesis will necessarily 
examine issues relevant to the prevalence, diagnosis and treatment of S. stercoralis infection, 
and will test the effectiveness of a “case finding and treatment” strategy in the control of this 
infection in an Australian Aboriginal community. 
Chapter one has dealt with the necessary background information and a review of the current 
literature on this subject. Chapter two reports on a cross sectional observational study of 
adults attending the health centres in the study community, testing them for both 
strongyloides infection and T2DM, and will establish the nature of the relationship between 
these two conditions. This will then establish a cohort of infected and un-infected subjects 
who can be followed over a three-year period in order to determine the outcomes of 
treatment, and enabling characterization of both the initial relationship between the two 
diseases, and the effects that treatment for strongyloides may have on subsequent metabolic 
parameters. Chapter three will examine the outcome at 6 months follow up in terms of the 
success of treatment for S. stercoralis and the presence of any factors, including T2DM, 
which might impact on this success. Chapter four will then examine the relationship of 
peripheral eosinophilia to strongyloides infection, both in regard to the predictive value of 
eosinophilia in the diagnosis strongyloides infection, and its relationship to T2DM. 
In a study such as this it is also important to acknowledge that Strongyloides stercoralis is a 
significant and potentially fatal infection for people living in these communities. There are 
continuing efforts, both in Australia and internationally, to improve the diagnosis, treatment 
and follow up of this condition, and to decide upon which strategies are likely to be most 
effective in the control and elimination of the infection from affected communities. In 
addition to issues of metabolic outcome, any study dealing with S. stercoralis is therefore 
obliged to deal where possible with these issues of diagnosis, treatment, follow up and 
community wide control. Chapter five will deal explicitly with this topic, and examine the 
outcomes in terms of treatment success at the three-year follow up of the cohort.  
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Finally, Chapter six will look at the metabolic outcomes after three years for patients treated 
for strongyloides, both for patients with pre-existing diabetes and those without, and with 
special consideration for those in whom treatment was not successful. The thesis will 
conclude with a discussion of the context and possible consequences of the findings in terms 
of both the strategies used to control S. stercoralis infection, and the effect that helminth 
infection has on glucose metabolism. As well as examining the central issue of the 
relationship between Strongyloides stercoralis infection and T2DM, the design of this study 
will allow questions regarding the prevalence of infection, the utility of ELISA testing in 
diagnosis and follow up, factors effecting treatment failure or success, and the effectiveness 
of a “case finding and treatment” strategy in the longer-term control of infection to be 
answered in the context of this community. This may then have broader implications for 
treatment and control of the infection both within Australia and worldwide. 
Each of Chapters two to six will constitute a separate peer reviewed published paper. 
References for each chapter have been rationalized and combined at the end of the thesis to 
minimize repetition. 
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Chapter 2 Strongyloides stercoralis Infection and T2DM: Evidence from an 
Australian Aboriginal Community 
2.1 Introduction 
The first stage in this thesis required the establishment of a cohort of patients in a community 
where both T2DM and infection with Strongyloides stercoralis were prevalent, in order to 
demonstrate any association between these two conditions. The Indigenous communities of 
northern Australia are an ideal setting for a study of this kind, with an extremely high 
prevalence of both conditions occurring in a setting where adequate resources exist for the 
appropriate diagnosis, treatment and follow up of patients. 
This cross sectional, observational study was, in itself, a project without precedent at this 
time. As noted, prior to the commencement of this study, very little had been published with 
regard to the relationship between helminth infection and type 2 diabetes mellitus, and the 
few studies that had appeared had all treated T2DM as the exposure and helminth infection as 
the outcome.45, 46, 57, 58 Furthermore, the one published study that had looked at the 
relationship between Strongyloides stercoralis infection and T2DM, conducted in a Brazilian 
endocrinology clinic and involving only small numbers of patients, found a positive 
association between the two conditions58. To this time, it remains the only study that has 
found a positive association between helminth infections and metabolic disease, suggesting 
that the population studied may have been in some way biased. The diabetic patients 
recruited to this study were a hospital based sample and therefore are unlikely to be 
representative of the wider diabetic population. It seems probable that T2DM patients 
recruited from a hospital endocrinology clinic would be biased toward those with relatively 
severe and poorly controlled disease, and as we shall see, this may in part explain the study 
findings.  
In contrast to this clinical study, laboratory investigations in 2010 and 2011 had given 
support to the theory that chronic helminth infection may result in improved glucose 
metabolism. Models demonstrating that eosinophilic infiltration of adipose tissue, as a result 
of experimental helminth infection, sustained the presence of alternatively activated 
macrophages which in turn increased insulin sensitivity in peripheral tissues through the 
action of anti-inflammatory cytokines suggested that chronic helminth infection may produce 
similar changes in a human population8, 9.  
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The survey was conducted in 2013 and 2014, and the results were published in early 2015. 
Hays R, Esterman A, Giacomin P, Loukas A, McDermott R, 2015. Does Strongyloides 
stercoralis infection protect against type 2 diabetes in humans? Evidence from 
Australian Aboriginal adults. Diabetes Res Clin Pract 107: 355-61. 
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2.2 Does Strongyloides stercoralis Infection Protect Against Type 2 Diabetes in 
Humans? Evidence from Australian Aboriginal adults 
2.2.1 Abstract 
Objective: To explore the relationship between infection with Strongyloides stercoralis and 
the likelihood of having type 2 diabetes mellitus (T2DM). 
Methods: Cross-sectional survey of 259 Aboriginal adults living in a remote community in 
northern Australia during 2013. Prior infection with S. stercoralis was determined by ELISA 
testing on serum. Main outcomes were eosinophil count, T2DM diagnosis, HbA1c, BMI, 
fasting lipids, Hb, blood pressure. 
Findings: Ninety-two participants (36%) had prior infection with S. stercoralis and 131 
(51%) had T2DM. Those with previous S. stercoralis infection (ELISA titre ≥0.3) were 61% 
less likely to have a diagnosis of T2DM than those uninfected, adjusted for age, triglycerides, 
blood pressure and BMI using propensity score (adjusted OR=0.39, 0.23-0.67, p=0.001).  
Interpretation: In this remote community where prevalence of both S. stercoralis and T2DM 
is very high, infection with S. stercoralis appears to significantly reduce the risk of T2DM in 
adults.  A plausible immunological mechanism has been identified in animal models. If 
confirmed, this result may have practical implications for the prevention of T2DM and 
associated metabolic disorders in humans. This finding should be explored further with 
animal models and with larger longitudinal studies in transitional populations where the risk 
of both conditions is high.  
Funding: No external funding was required for this study. 
2.2.2 Introduction and background 
Strongyloides stercoralis (S. stercoralis) is a soil transmitted helminth (STH) infection that 
affects an estimated 30 to 100 million people worldwide, mostly in the developing world. 
The worm is transmitted through skin contact with faecal matter or contaminated soil 
containing the infective larva. Once established S. stercoralis, uniquely amongst STH 
infections, has the capacity for an auto-infective cycle, enabling the development of chronic 
infection even in the absence of further exposure. The fact that it may be asymptomatic for 
many years, or even decades, means that even amongst the neglected STH infections it has 
remained neglected. Historically, difficulty in establishing a gold standard for the diagnosis 
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of infection, and the relative absence of effective treatment has hindered both research into 
and treatment of this condition14, 24. 
Many of the developing countries where S. stercoralis is prevalent are now facing an 
approaching epidemic of obesity and type 2 diabetes mellitus (T2DM), however it is 
currently unclear whether these conditions are interrelated.   Previous research has explored 
the potential relationship between helminth infection and chronic inflammatory diseases such 
as asthma, inflammatory bowel disease, and in particular, Type 1 diabetes mellitus (T1DM)59, 
60. While a negative association between helminth infection and T1DM has been described, 
research into the relationship between T2DM and helminth infection has been limited by the 
fact that these two conditions, in general, only co-exist in high prevalence in “transitional” 
societies, where access to the necessary tools for the diagnosis of infection is often limited. 
There is however, a growing body of evidence from studies using experimental animal 
models to suggest that helminth infection is able to affect the development of metabolic 
illnesses such as insulin resistance and T2DM through a process of immunomodulation9, 61. 
Very little research attention has been given to the possible interaction between S. stercoralis 
and T2DM in clinical studies. A small observational study conducted in Brazil suggested a 
positive association between the two conditions58. A larger study of risk factors for the 
presence of S. stercoralis in India, however, suggested the opposite57. A further study in India 
examined the relationship between T2DM and another chronic nematode infection, lymphatic 
filariasis (LF), and found a negative association. In addition, they found evidence for an 
altered immune response in diabetic patients with LF46.  
The Aboriginal communities of Northern Australia are unique in that they are home to some 
of the highest recorded prevalence of S. stercoralis infection in the world34 in addition to 
being hyper-endemic for T2DM62. The communities of the east Kimberley region are no 
exception to this. A survey of one community in 1990 registered a prevalence of 37% for  
S. stercoralis infection63. A recent audit of the clinic records suggested that between 20 and 
30% of adults across the region have T2DM, and that approximately 50% of all adult patients 
presenting to the community clinics have a diagnosis of T2DM (Internal audit 2012). This 
study setting therefore provides a possibly unique opportunity in which to examine the 
relationship between these two chronic illnesses. We explore here the relationship between S. 
stercoralis infection and T2DM in a transitional population where the incidence of both 
conditions is high. 
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2.2.3 Methods 
2.2.3.1 Study setting 
The study communities comprise three related settlements within a 100km radius on the edge 
of the Tanami desert, about 800 km east of the town of Broome. The population is nearly 
exclusively indigenous and numbers approximately 1500 individuals spread between the 
three communities. Medical services are provided through the Kimberley Aboriginal Medical 
Services Council, which is centred in Broome. This is also the location of the nearest hospital 
and laboratory services 
2.2.3.2 Patients 
Prior to this study very little testing or treatment of S. stercoralis had taken place in the study 
communities. There was a well-established practice of giving patients short courses (one to 
three days) of albendazole 400 mg for presumed helminth infection, and the occasional dose 
of ivermectin had been given on an empirical basis. In April 2012 the decision was made to 
begin testing and treating patients for S. stercoralis according the best practice guidelines of 
the Australian Strongyloides working group32. Accordingly, patients attending the clinic were 
offered testing and treatment for the infection on an opportunistic basis. As the presumed 
prevalence of S. stercoralis in the region was about 37%63, all Indigenous patients resident in 
the study communities were considered to be at risk of infection.  
Data was extracted including the age, sex, date of testing, S. stercoralis ELISA titre, 
haemoglobin, total eosinophil count, percentage eosinophilia, height, weight, calculated BMI, 
diabetic status and HbA1C Triglyceride level, HDL and total cholesterol. Eosinophilia was 
defined as a total eosinophil count of 0.50 x109/L or greater. In addition, data was recorded 
regarding the past treatment, if any, with anthelmintic drugs. Patients were excluded from the 
study if they had received past treatment with ivermectin in the absence of serological testing. 
2.2.3.3 Serological testing 
S. stercoralis ELISA testing was ordered, often in conjunction with other routine laboratory 
investigations. Serological testing for S. stercoralis using ELISA has been shown to be 
adequate for both diagnostic and sero-survey purposes25. Testing was performed by Pathwest 
Laboratory in Perth Western Australia, using the commercial strongyloides IgG ELISA 
(DRG laboratory). The reference values, in units of absorbance, given for this test were as 
follows: Less than 0.2 –Negative; 0.2 to 0.4 –Equivocal; Greater than 0.4 –Positive. 
However, as was noted by the laboratory, these ranges were developed in a metropolitan 
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population where the prevalence of S. stercoralis was 1/10000 individuals. In order to reduce 
the possibility of false negative results it was decided to employ a modified range. All values 
greater than or equal to 0.30 were considered positive and treated. All values less than 0.30 
were considered equivocal and were re-tested after a period of 6 months. As the level of 0.30 
was chosen purely on clinical grounds as a means of determining when to treat, analysis of 
the relationship between strongyloides serology and T2DM was repeated at both lower (0.20) 
and higher (0.40) cut-off points.  The case definition for S. stercoralis infection therefore was 
an Aboriginal adult older than 20 years, resident in the study communities, with a  
S. stercoralis ELISA titre of 0.30 or greater. 
2.2.3.4 Determination of T2DM status 
Diabetes was defined in this group as an HbA1C reading of 6.5% or greater, or a random 
blood glucose of more than 11.1 mmol/l, or a fasting blood glucose of more than 7.0 mmol/l, 
either at the time of testing, or in the past in patients already receiving treatment for diabetes. 
2.2.3.5 Anthelminthic treatments 
Patients identified as positive for S. stercoralis were treated with two doses of ivermectin 0.2 
mg/kg given two weeks apart, and were recalled for re-testing after a period of 6 months post 
treatment. All patients identified as equivocal were recalled for repeat testing after a period of 
6 months. 
2.2.3.6 Regulatory commitments 
The protocol for this study was approved by the Kimberley Aboriginal Health Planning 
Forum. Ethical approval for the study was obtained through the Western Australian 
Aboriginal Health Ethics Committee (HREC Reference 515).  
2.2.3.7 Funding 
No external funding was required for this project 
2.2.4 Statistical analysis  
Descriptive statistics included mean, medians (where data was not normally distributed) and 
percentages, and their respective 95% Confidence Intervals (CI). Comparisons of variables 
between those with and without diabetes used independent samples t-tests and Mann-
Whitney U-tests for continuous variables, and chi-square tests for categorical variables. 95% 
CI for medians was obtained by bootstrapping. The association between being ELISA 
positive for S. stercoralis and diabetes was assessed using logistic regression. A propensity 
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score was first created using age, BMI, triglycerides and systolic blood pressure as predictors 
of positivity. Multiple imputation using five sets of data and assuming a multivariate normal 
model was then used to impute missing propensity scores. Age, sex, systolic and diastolic 
blood pressure were used for the imputation process.  Finally, the odds ratio adjusted for the 
propensity score was obtained based on the pooled results. All analyses were undertaken 
using STATA v13. 
2.2.5 Results 
Approximately half (51%) of the subjects included in the study had T2DM and 36% had 
evidence of S. stercoralis infection (ELISA titre >=0.3) (Table 2.1). There were significant 
differences in those participants who had T2DM and those who did not. As expected, those 
with T2DM were older, heavier, had higher blood pressure and higher triglycerides (Table 
2.2). Interestingly, those with T2DM were 61% less likely to have a positive ELISA test for 
S. stercoralis (crude odds ratio 0.37, 95% CI 0.22-0.62) (Table 2.3). This relationship 
remained after adjustment for age, SBP, triglycerides and BMI (adjusted odds ratio 0.39, 
0.23-0.67; p=0.001). The relationship also persisted when the cut-off point for diagnosis of 
strongyloides was set at either 0.20 or 0.40 units.  
Amongst the 92 cases where S. stercoralis infection was identified, there was a significantly 
higher incidence of eosinophilia in individuals with diabetes compared with the non-diabetics 
(Table 2.4). 
Follow up of the “equivocal” group over an average of 228 days revealed only 3 new cases in 
this period, and demonstrated an excess of falling or steady S. stercoralis titres compared to 
rising titres, [Falling (or steady) titre 66.4%, Rising titre 33.6%] and a significant overall fall 
in the average titre [Median Antibody titre (95% CI) Pre 0.08 (0.08 – 0.10) Post 0.06 (0.05 – 
0.07); p = <0.001]. 
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Table 2.1 Clinical characteristics of the study participants (N=259). 
Variable N 
Mean, Median 
or % 95% CI 
Age (years) 259 43.4 41.7 - 45.1 
Male  106 40.9% 35.1 - 47.1 
Weight (Kg) 253 81.6 78.9 - 84.4 
BMI (kg/m2) 245 29.7 28.7 - 30.6 
Hb (g/l) 249 133.8 131.7-135.8 
HbA1c % 220 6.8a 6.5 - 7.1 
SBP (mmHg) 259 126.8 124.5 - 129.1 
DBP (mmHg) 259 79.7 78.3 - 81.1 
Cholesterol (mmol/l) 228 4.6 4.4 - 4.7 
HDL (mmol/l) 227 0.90 0.87- 0.93 
Triglycerides (mmol/l) 227 2.1a 1.9 - 2.3 
Diabetes  131 50.6% 44.5 - 56.7 
Eosinophil count 237 0.43a 0.38 - 0.48 
Eosinophil % 236 5.55a 4.71 - 6.39 
E (ELISA) titre 259 0.15a 0.12-0.18 
% E-titre ≥ 0.3 92 35.5 29.7 - 41.7 
a Median 
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Table 2.2 Characteristics of participants by diabetic status. 
 Not diabetic (N=128) Diabetic (N=131) Sig.a 
Mean (95%CI) Age (years) 40.4 (37.9 - 43.0) 46.3 (44.0 - 48.5) <0.001 
Gender %   0.268 
 Male  37.5 (29.5 - 46.3) 44.3 (35.9 - 52.9)  
 Female 62.5 (53.7 - 70.5) 55.7 (47.1 - 64.1)  
Mean (95%CI) Weight (Kg) 76.2 (72.5 - 79.9) 86.8 (82.9 - 90.7) <0.001 
Mean (95%CI) BMI (kg/m2) 28.0 (26.7 - 29.4) 31.2 (29.9 - 32.6) 0.001 
Mean (95%CI) Hb (g/l) 133.7 (130.6-136.6) 133.9 (131.0-136.9) 0.878 
Median (95%CI) HbA1c % 5.8 (5.7 - 5.9) 8.1 (7.7 – 8.5) <0.001 
Mean (95%CI) SBP (mmHg) 122 (120 -125) 131 (128 - 135) <0.001 
Mean (95%CI) DBP (mmHg) 78 (76 - 80) 82 (80 - 84) 0.095 
Median (95% CI) Tot. Chol. 
(mmol/l) 
4.4 (4.1 - 4.7) 4.3 (4.0-4.5) 0.197 
HDL (mmol/l) 0.92 (0.87 - 0.96) 0.88 (0.84 - 0.92) 0.260 
Median (95% CI) Trig. 
(mmol/l) 
1.7 (1.4 - 2.0) 2.6 (2.3 - 2.9) <0.001 
ELISA   <0.001 
 <0.3 53.1 (44.4 - 61.7) 75.6 (67.4 - 82.2)  
 ≥0.3 46.9 (38.3 - 55.6) 24.4 (17.8 - 32.6)  
Eosinophils  0.41 (0.35 – 0.47) 0.44 (0.38 – 0.50) 0.236 
a Independent samples t-test or Mann-Whitney U-test for continuous variables, and chi-square test for gender 
and ELISA category 
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Table 2.3 Association between positivity for S. stercoralis and diabetic status. 
Serology cut-off Variable 
Odds Ratio 
(OR) 95% CI (OR) Sig.a 
≥0.3 
 
Positivity 0.37 0.22 – 0.62 <0.001 
Positivityb 0.39 0.23 – 0.67 0.001 
≥0.2 
 
Positivity 0.49 0.30 – 0.81 0.005 
Positivityb 0.49 0.30 – 0.83 0.007 
≥0.4 
 
Positivity 0.42 0.24 – 0.73 0.002 
Positivityb 0.43 0.25 – 0.75 0.003 
a From logistic regression 
b Adjusted for Age, triglycerides, systolic blood pressure and BMI using a propensity score 
 
 
 
 
 
Table 2.4 Characteristics of ELISA Positive patients by diabetic status. 
Variable Non-Diabetic (N=60) Diabetic (N=32) Sig. 
Mean (95% CI) Age  41.2 (36.9 – 45.6) 46.8 (42.7 – 50.9) 0.098a 
Gender - male 35% 50% 0.162c 
BMI 27.8 (28.3 – 35.4) 31.8 (28.3 – 35.4) 0.031a 
Eosinophilia 55.5% 71.9% 0.110c 
Median (95% CI) eosinophil count  0.54 (0.42 – 0.65) 0.78 (0.47 – 1.09) 0.020b 
Median (95% CI) Antibody titre  0.57 (0.37 – 0.77) 0.86 (0.66 – 1.07) 0.244b 
Median (95% CI) Triglycerides   1.70 (1.29 – 2.11) 2.05 (1.44 – 2.66) 0.105b 
a Independent samples t-test 
b Mann-Whitney U-test 
c Chi-squared test 
 
2.2.6 Discussion 
Our study found a strong negative association between S. stercoralis infection and T2DM in 
this community. This negative association persists when corrected for age, gender and body 
mass index. The obvious limitation of this cross sectional observational study is that causality 
cannot be implied. However, knowledge of the natural history and pathophysiology of  
S. stercoralis infection and T2DM can assist in developing some explanation for these 
observations. 
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As noted above, S. stercoralis is able to produce a chronic, self-sustaining infection. The 
proportion of acute infections that progress to this chronic stage is, however, unknown. 
Studies have demonstrated that, as with other STH infections, the prevalence increases until 
late adolescence and then remains relatively constant throughout adult life13.  
T2DM on the other hand, is a metabolic illness that begins to manifest clinically in late 
adolescence, and then increases in prevalence progressively into mid-life. It is difficult to 
conceive of a mechanism by which the presence of T2DM might protect against S. stercoralis 
infection, or prevent the development of a chronic infection.  
A more plausible explanation for the data is that the presence of chronic S. stercoralis 
infection can, over time, protect against the development of T2DM.  
The question as to whether the infections are acute or chronic is clearly important. There is 
no established protocol by which the chronicity of any particular strongyloides infection can 
be determined. Clinical assessment in communities where the infection is common is of little 
value as the onset of infection is often not apparent, or produces only non-specific symptoms, 
and patients with long standing infections are often symptom free64. 
Some conclusions may be drawn from the rate of acquisition of infection in this community. 
The 167 patients who were initially negative for S. stercoralis infection were followed up for 
an average of 287 days, and in this time only 3 patients acquired the infection according to 
the criteria used in this study. This would suggest that the acquisition rate for S. stercoralis 
amongst previously uninfected adults is relatively low and therefore imply that the majority 
of infections seen here are longstanding in duration. 
Follow up of the negative patients demonstrates a preponderance of falling or steady titres 
compared to rising ones, and an overall significant reduction in the average titre over the 
follow up period. This could suggest that negative patients with measurable titres in fact 
represent patients who have been exposed to the parasite in the past, but in whom a patent 
chronic infection has not been established. 
Given that the data in this study suggests that chronic infection with S. stercoralis can protect 
against the development of T2DM, what mechanisms can be suggested to explain this 
observation? 
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A simple, nutrition-based explanation, where the worm competes with the host would seem 
unlikely. It is not born out by the data, as the association is unrelated to BMI. It would also 
seem unlikely on pathophysiological grounds. Chronic infections with S. stercoralis, in the 
absence of hyperinfection, are known to comprise only very low numbers of adult worms13 
each only about 2 mm long, suggesting that the nutritional burden of chronic infection is 
likely to be low. Gastrointestinal symptoms, in particular chronic diarrhea and mal-absorption 
have been described mainly in acute infections and in children, and are not commonly 
reported in chronic infections, particular in communities where the infection is common64. 
 It is plausible that the presence of strongyloides infection may have an effect on the 
microbiota of the gut and influence the prevalence of T2DM in this way. It is known that the 
gut microbiota is altered in diabetic patients compared to non-diabetic41 and animal studies 
have demonstrated the effect that helminths may have on gut bacteria65. Recently 
experimental hookworm infection in humans has been shown to cause an altered microbiota 
in some instances66. 
Numerous studies have now demonstrated that the development of T2DM in adult life is 
more common among low birth weight (LBW) babies67.  Furthermore, this association is 
strongest amongst LBW babies who subsequently gain weight rapidly in the first decade of 
life68. Interestingly, longitudinal studies underway amongst Indigenous populations in 
northern Australia have yet to demonstrate this association, and it has been postulated that 
this may be because the population studied is failing to gain weight in early life69. Australian 
Aboriginal children commonly suffer numerous parasitic and bacterial infections early in life, 
which may contribute to this lack of rapid weight gain. It is plausible that S. stercoralis 
infection, acquired early in life and leading to a subsequent chronic infection, might 
contribute to lack of weight gain and failure to thrive in the first decade of life, and 
subsequently reduce the incidence of T2DM later in life. Clearly, studies that examine the 
prevalence of S. stercoralis infection in children in these communities and its association 
with weight gain, BMI and nutritional status, would be of great benefit. 
An equally compelling explanation for the observed association is that chronic S. stercoralis 
infection is able to reduce the incidence of T2DM through a process of immunomodulation. 
Chronic helminth infections elicit a modified T helper type 2 (Th2) immune response in the 
host mediated through a reduction in pro-inflammatory cytokines such as IFN- and TNF- 
and an increase in anti-inflammatory cytokines such as IL-10 and TGF-, thereby promoting 
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the survival of the parasite and reducing the risk of inflammatory injury in the host70. There is 
also evidence that immunomodulation may influence the development of metabolic illnesses 
such as insulin resistance and T2DM. Clinical studies have suggested that the occurrence of 
T2DM is related to the overall level of inflammation present over time71. Conversely there 
are studies that demonstrate a negative association between IL-10 and T2DM72. If chronic 
infection with S. stercoralis were responsible for producing a low inflammation environment 
in the host then this could explain the subsequent lower incidence of T2DM. 
The association between chronic inflammation in adipose tissue and the development of 
insulin resistance and T2DM has been long established35. This inflammation is mediated 
through the Th1 immune response and “classically activated” macrophages, and involves 
increased levels of pro-inflammatory cytokines such as TNF and IL-1β. Conversely, in lean 
individuals adipose tissue is infiltrated by alternatively activated macrophages (AAM) that 
reduce inflammation and promote insulin sensitivity through an IL -10 and regulatory T cell-
mediated process9. Experimental studies have shown that eosinophils infiltrating adipose 
tissue are central to recruiting and maintaining AAM through IL-4 and IL-13, and that Th2 
responses and eosinophilia in mice with experimental helminth infections are capable of 
increasing insulin sensitivity8.  
In our study, we observed a significantly higher eosinophil count amongst the patients with 
T2DM compared to those without. As this is a cross sectional observational study, causality 
cannot be implied. The observation could be explained if the immune response amongst 
diabetics were for some reason more vigorous than that that amongst non-diabetics. 
However, since the rate of eosinophilia and the overall eosinophil count in S. stercoralis 
infection tend to be higher in early infections and diminish with the duration of infection73, a 
more likely explanation would be that the T2DM group contains, on average, more acute or 
recent infections and consequently less chronic infections than the group without T2DM. 
It is possible therefore to propose a model where acute infection with Strongyloides 
stercoralis and the subsequent Th2 immune response leads either to worm killing and 
resolution of the infection in some cases, or the establishment of a chronic well adapted 
infection, with a modified Th2 immune response, ongoing infiltration of adipose tissue with 
eosinophils and AAM’s, and a subsequent reduction in insulin resistance in others (Figure 
2.1).  
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In the first instance the resolution of infection leads to a return to baseline levels of risk for 
T2DM, while the presence of chronic S. stercoralis infection in the other group results in a 
lower prevalence of T2DM. 
 
Figure 2.1 Potential immuno-metabolic pathways for Strongyloides infection and T2DM risk. 
2.2.7 Conclusion 
This study provides, for the first time, evidence that chronic infection with S. stercoralis may 
protect against the development of T2DM in humans. In doing so it provides clinical and 
epidemiological evidence in support of the animal models that show that helminth infections 
can result in an improved metabolic profile through a process of immunomodulation.  
Increasing attention is being given to the possible role of anti-inflammatory treatments in the 
management of established T2DM and the importance of “immuno-metabolism” in this 
process, but attention has thus far concentrated on treatment rather than prevention74. 
Immunomodulation by helminth infections is mediated by excretory/ secretory proteins 
(ESP) either elaborated by the worm, or present on its surface. .Studies have identified many 
of these proteins in various helminth infections, and in some cases the mechanism by which 
they produce their effect75. If the effect of S. stercoralis infection on metabolic processes can 
be confirmed, and a protein or proteins identified which are responsible for this effect, then it 
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could provide the prospect of developing a therapeutic agent capable of preventing or 
delaying the onset of T2DM in susceptible populations. 
The authors report no conflicts of interest. We would like to formally acknowledge the role 
of the peoples of the Kutjungka region in this study. 
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Chapter 3 Strongyloides stercoralis Infection and T2DM: 
Implications for Treatment Outcomes 
3.1 Introduction 
Having established a relationship between Strongyloides stercoralis infection and T2DM in a 
cross sectional observational study, the opportunity then exists to follow the cohort of 
infected and uninfected patients in a longitudinal study. This would enable examination of 
the effect of prior T2DM on treatment outcomes, the long-term effect that treatment of adults 
would have on the prevalence of infection in the community, and the effect that treatment for 
strongyloides infection might have on the incidence and control of T2DM in this population.  
The initial follow-up of our cohort was conducted after 6 months, when changes in ELISA 
serology levels could be expected to reflect the success or otherwise of treatment. Metabolic 
outcomes were not measured after this relatively short time period as it was thought unlikely 
that any appreciable effect on diabetic outcomes would be apparent. The outcome of 
treatment however, and any relationship it might have to prior T2DM status should be 
apparent after 6 months, which is within the usual follow up period recommended to 
demonstrate a fall in strongyloides ELISA titre, and therefore treatment outcome26. If a 
relationship could be established between T2DM and treatment outcome then this would give 
support to the theory that an interaction exists between T2DM and the immunological 
reaction to S. stercoralis infection. Clinical experience holds that bacterial and viral 
infections are often more difficult to control in patients with T2DM, but no such relationship 
has been demonstrated in helminth infections.  
This study was also of interest to clinicians concerned with the control of S. stercoralis, as 
follow up studies of treated strongyloides patients were uncommon both in Australia and 
internationally, and had been characterized by relatively large numbers lost to follow up after 
even relatively short time periods34, 76. It has been thought that ivermectin is an effective 
treatment for S. stercoralis in this population, but in fact good evidence for this was lacking, 
and there had been no published studies which examined the effect of factors such as T2DM 
in the outcome of treatment.  
Follow up of our cohort at 6 months post treatment was completed in 2014 and the results 
were published in early 2015. 
 34 
Hays R, Esterman A, McDermott R, 2015. Type 2 Diabetes Mellitus is associated with 
Strongyloides stercoralis treatment failure in Australian Aboriginals. PLoS Negl Trop 
Dis 9: e0003976. 
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3.2 Diabetes Mellitus is Associated with Strongyloides stercoralis Treatment 
Failure in Australian Aboriginals 
3.2.1 Abstract 
Objective: To explore the efficacy of ivermectin in the treatment of serologically diagnosed 
cases of Strongyloides stercoralis (S. stercoralis) infection in an Aboriginal community and 
to describe factors that may influence the outcome of treatment. 
Methods: Longitudinal study of a group of 92 individuals with serologically diagnosed  
S. stercoralis treated with ivermectin and followed up over a period of approximately 6 
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months. Main outcomes were serological titres pre and post treatment, diabetic status, and 
duration of follow up. 
Findings:  Treatment success was achieved in 62% to 79% of cases dependent on the 
methods employed for the diagnosis of infection and assessment of treatment outcome. Type 
2 Diabetes Mellitus (T2DM) was found to be significantly associated with treatment failure 
in this group for two of the three methods employed.  
Interpretation: Ivermectin has been confirmed as an effective treatment for S. stercoralis 
infection in this setting. T2DM appears to be an independent risk factor for treatment failure 
in this population, and plausible mechanisms to explain this observation are presented 
Author Summary: In this study, we examine the treatment of the intestinal worm infection 
Strongyloides stercoralis, a soil transmitted helminth that is common in the developing world 
and in the Aboriginal communities of northern Australia. Oral ivermectin is generally 
accepted as the treatment of choice for this condition. We screened an Aboriginal community 
for strongyloides infection over the course of 2 years and measured the outcome of treatment 
in the 92 cases we found. This study measures the success or otherwise of treatment, and 
looks at whether there are any factors that could influence the rate of treatment failure. The 
results suggest that ivermectin is an effective treatment for strongyloides in this setting, and 
that pre-existing Type 2 Diabetes Mellitus is a risk factor for treatment failure, an observation 
of great interest in Aboriginal communities where the prevalence of both conditions is very 
high. We discuss some possible mechanisms to help explain this previously unknown 
relationship. 
3.2.2 Introduction 
S. stercoralis is a soil transmitted helminth infection and as such is a neglected tropical 
disease. It is thought to have a worldwide prevalence of at least 100 million people, and is 
endemic in regions where people are in contact with fecal material or contaminated soil. The 
majority of infections in the inhabitants of endemic regions are thought to be asymptomatic, 
but it can produce a variety of gastrointestinal and skin symptoms. Unusually, S. stercoralis 
has the capacity for an auto-infective cycle, and in the presence of host immunosuppression 
hyper-infection syndrome may develop, resulting in severe morbidity and even death.14  
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In the past, the absence of a gold standard for the diagnosis of this infection, uncertainty as to 
the most effective treatment, and difficulty in establishing whether a cure has been achieved, 
has posed problems for research into this condition.24 
Traditional microbiological methods for detecting strongyloides infection, including 
concentration techniques for fecal examination such as the Baermann and Harada-Mori 
techniques, and agar plate culture, require the use of repeated, fresh fecal samples, and have 
been troubled by low sensitivity. [2] This is particularly so when assessing patients for cure, as 
larval output can be low and intermittent leading both to under-estimates of the prevalence of 
the infection, and over- estimates of the effectiveness of treatment.29. 
In recent years serological methods for the detection of strongyloides infection have been 
developed and advocated as being suitable for both clinical assessment and epidemiological 
surveys. Furthermore, there is increasing evidence for the use of serological tests to follow up 
treatment and assess cure.25 
Various medications have been employed for the treatment of strongyloides infection 
including albendazole, thiobendazole and ivermectin. It is now generally accepted that 
ivermectin is the most effective treatment and should be the treatment of choice where 
available, although questions still remain regarding the best dosing schedule29. 
Similarly, the best means of follow up after treatment and the appropriate time frame in 
which to do this has yet to be established. Follow up of ELISA serology has employed either 
a fall from a positive titre to a negative (treatment success), or a proportional fall in titre such 
that the ratio of post to pre-treatment titres is less than 0.6(treatment effectiveness)25 The 
lengthy time frame required for the follow up of cases has often led to high rates of patients 
lost to follow up.76. 
Strongyloides infection is extremely common in Indigenous communities of the tropical 
regions of northern Australia with a prevalence of 41% in some settings.34 32  Despite 
increasing access to serological tests and adequate treatment, screening and treatment 
programs remain intermittent, and little is known about the efficacy of ivermectin under 
Australian conditions, with a recent review noting the paucity of adequate follow up studies 
following treatment76. 
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In this study, we report on the treatment and follow up of 92 serologically diagnosed cases of 
S. stercoralis infection in a remote Aboriginal community, and the effect of a variety of 
epidemiological factors and co-morbidities on the outcome of treatment. 
3.2.3 Materials and methods 
3.2.3.1 Study setting 
This study was conducted in three isolated indigenous communities located on the edge of 
the Tanami desert in the Kimberley region of Western Australia. The communities are inter-
related and consist of a mobile population of approximately 1500 people. A medical clinic in 
each community provides primary care and emergency services, and the nearest hospital and 
laboratory services are some 800km away in the town of Broome.  
3.2.3.2 Patients 
Prior to this study the approach to testing and treating for helminth infection had been 
intermittent and largely empirical. Patients suspected of having a worm infection were 
generally given a three-day course of albendazole 400mg without any laboratory testing, and 
very little ivermectin had been used. In April 2012 it was decided to adopt the best practice 
guidelines of the Australian Strongyloides working group32 and patients attending the clinic 
were subsequently offered testing and treatment on an opportunistic basis for S. stercoralis 
infection. As the presumed prevalence of S. stercoralis in the region was about 37%63, all 
Indigenous patients resident in the study communities were considered to be at risk of 
infection.  
Data were extracted including the age, sex, date of testing, S. stercoralis ELISA titre, 
haemoglobin, total eosinophil count, percentage eosinophilia, height, weight, calculated BMI, 
diabetic status and HbA1C triglyceride level, HDL and total cholesterol. 
Eosinophilia was defined as a total eosinophil count of 0.50 x109/L or greater. T2DM was 
defined in this group as an HbA1C reading of 6.5% or greater, or a random blood glucose of 
more than 11.1 mmol/l, or a fasting blood glucose of more than 7.0 mmol/l, either at the time 
of testing, or in the past in patients already receiving treatment for diabetes. 
In addition, data were recorded regarding the past treatment, if any, with anthelmintic drugs. 
Patients were excluded from the study if they had received past treatment with ivermectin in 
the absence of serological testing. 
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The patient group in this study constituted part of that utilized in an earlier published study77 
3.2.4 Serological testing 
S. stercoralis ELISA testing was performed by Pathwest Laboratory in Perth Western 
Australia, using the commercial Strongyloides IgG ELISA (DRG laboratory). The reference 
values for this test were established in a low prevalence (<1/10000) population, with > 0.40 
units of absorption held to be positive, < 0.20 units negative, and values in between 
considered “equivocal”.  As this study was being conducted in a presumed high prevalence 
setting, and in the interests of avoiding false negative results, a modified range was 
employed. Values greater than or equal to 0.30 units were considered positive and treated. All 
values less than 0.30 units and greater than zero were considered equivocal and were re-
tested after a period of 6 months.  
Clinical treatment success was defined as a fall in titre to < 0.30 units. Only patients who 
failed to achieve this were, where possible, retreated with ivermectin. 
3.2.5 Anthelminthic treatments 
Patients identified as positive for S. stercoralis under these criteria were treated under direct 
observation with two doses of ivermectin 0.2 mg/kg given two weeks apart. All patients, 
whether positive or equivocal, were recalled for re-testing after a period of 6 months. 
Although all patients were recalled after 6 months, difficulties in locating subjects for follow 
up resulted in a wide range (83 to 498 days, median 214 days) of follow up periods. 
3.2.6 Ethics statement 
The process of obtaining community engagement, consent and ethical approval began in 
2012-2013. A process of community and institutional consultation and education was 
undertaken. Staff at the community clinics, including Aboriginal health workers, nursing staff 
and administrative staff were educated in informal sessions regarding the nature and 
importance of Strongyloides infection in Aboriginal communities. In addition, key members 
of the community including elders, the community council and traditional healers were 
included in the process. Approval of the project was then sought from the KAHPF 
(Kimberley Aboriginal Health Planning Forum) which is the peak community consultation 
body in the Kimberley. Approval was received on April 5 2013 and subsequent application 
for ethical approval was sought from the Western Australian Aboriginal Health Ethics 
committee (WAAHEC) and received on November 1 2013 (HREC App 515). Finally, 
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application was made for ethical approval from the James Cook University (JCU) Health 
ethics committee and was received on September 21 2015. During the course of the project 6 
monthly reports on progress were made to the WAAHEC. In addition, with each published 
paper approval was sought from WAAHEC prior to publication. Copies of each paper were 
provided to the KAHPF along with “plain language” summaries intended for publication in 
the KAHPF community newsletter. Lastly, summaries in the form of “talking points” were 
provided for clinic workers to provide feedback to patients and community members at each 
stage.” 
Once the decision had been taken to test and screen for strongyloides was taken, as no tests, 
treatments or interventions were undertaken apart from those required for the accepted 
Australian best practice32 for the diagnosis and treatment of strongyloides infection, and all 
data was de-identified before storage, verbal consent was considered adequate. Literacy 
levels in written English are low in the communities studied. All subjects were 21 years of 
age or older. Verbal consent was obtained by medical and nursing staff at the time of initial 
testing and stored electronically.  
3.2.7 Statistical analysis  
As the decision to treat at a level of 0.30 units was based only on clinical grounds, and 
because the best means for determining treatment failure remains uncertain, the data obtained 
were analyzed in three different ways. 
The first definition of treatment failure was an initial titre of ≥0.30 units followed by a 
subsequent post-treatment reading of ≥0.30 units.  In a second analysis failure to achieve 
treatment “effectiveness”, that is a titre ratio ≥0.60 post-treatment compared to pre-treatment, 
was the measure of treatment failure. Lastly, the analysis was repeated using the conventional 
≥0.40 units as the cut-off point for positivity, and ≥0.40 units post treatment as the measure 
of treatment failure. 
Descriptive statistics are provided with means, median, percentages and their 95% confidence 
intervals.  Bootstrapping was used to obtain the confidence intervals for medians, whereas 
exact binomial confidence intervals are provided for percentages. Comparisons between 
those with and without diabetes were tested using independent samples t-tests, Mann-
Whitney U-tests and chi-squared tests for Normally distributed continuous variables, skewed 
continuous variables and proportions respectively. Log binomial generalized linear models 
were used to assess the association between diabetic status and treatment failure after 
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adjusting for age, sex, initial titre, follow up period and eosinophilia, and HbA1c (%) as a 
predictor of treatment failure. All analyses were undertaken using the Stata 13 statistical 
package.  
3.2.8 Results 
The characteristics of the 259 patients in this study, and the follow up for the 92 positive 
cases are summarized in tables 1 and 2.  Follow up serology was performed in 87 of the 92 
patients treated (94.6%).  Of the 5 patients not re-tested, one was diabetic and 4 were non-
diabetic. One patient had deceased, one was in the prison system and 3 were lost to follow 
up. 
Treatment failure as defined by a post-treatment titre of ≥0.30 was seen in 38% of patients.  
Using the ratio of post-treatment to pre-treatment titre of ≥0.60, 26% of patients had 
treatment failure. If only those with an initial titre of ≥0.40 and a subsequent reading of ≥0.40 
are defined as a failure, then the treatment failure rate was 21%. The percentage of diabetic 
and non-diabetic patients achieving a post treatment titre of < 0.30 is shown graphically in 
Figure 3.1. 
T2DM was predictive of treatment failure after adjustment for age, sex, initial titre, follow up 
period, treatment interval and eosinophilia, for both cut off points of 0.30 units (p =0.025) 
and 0.40 units (p= 0.006). It was not predictive of failure to achieve treatment “effectiveness” 
(post to pre-treatment ratio of >0.60). 
In addition, follow up of the “equivocal” group (initial titre <0.30, N=167) over an average of 
220 days revealed only 3 new cases in this period (1. Female age 53, pre titre 0.19 –post 0.30, 
2. Female 43, pre 0.15-post 0.43, 3. Female 30, pre 0.18-post 0.30) suggesting that treatment 
failures were unlikely to represent incidences of re-infection. 
Analysis was performed to determine whether HbA1C, measured as a percentage, was 
predictive of treatment failure (defined as post treatment titre ≥ 0.30) in the diabetic group 
and revealed only a statistically insignificant positive association (RR 1.085 95% CI 0.963-
1.222 p= 0.179). 
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Table 3.1 Clinical characteristics of the study participants (N=259). 
Variable N 
Mean, 
Median or % 95% CI 
Age (years) 259 43.4 41.7 - 45.1 
Male  106 40.9% 35.1 - 47.1 
Weight (Kg) 253 81.6 78.9 - 84.4 
BMI (kg/m2) 245 29.7 28.7 - 30.6 
Hb (g/l) 249 133.8 131.7-135.8 
HbA1c % 220 6.8a 6.5 - 7.1 
SBP (mmHg) 259 126.8 124.5 - 129.1 
DBP (mmHg) 259 79.7 78.3 - 81.1 
Cholesterol (mmol/l) 228 4.6 4.4 - 4.7 
HDL (mmol/l) 227 0.90 0.87- 0.93 
Triglycerides (mmol/l) 227 2.1a 1.9 - 2.3 
Diabetes  131 50.6% 44.5 - 56.7 
Eosinophil count 237 0.43a 0.38 - 0.48 
Eosinophil % 236 5.55a 4.71 - 6.39 
E (ELISA) titre 259 0.15a 0.12-0.18 
% E-titre ≥ 0.3 92 35.5 29.7 - 41.7 
a Median 
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Table 3.2 Characteristics and outcomes for positive cases by diabetes status with 95% CI.   
 
No diabetes (N=60) 
Type 2 Diabetes 
(N=32) Sig.a 
Age (years) Mean  41.2 (36.9 – 45.6) 46.8 (42.7 – 50.9) 0.098 
Male (%)  33.3 (22.0 – 47.0) 50.0 932.0 – 68.0) 0.119 
Weight (Kg) Mean   74.2 (68.6 – 79.7) 89.4 (68.6 – 79.7) 0.005 
BMI (kg/m2) Mean  27.8 (25.8 – 29.8) 31.8 (28.3 – 35.4) 0.031 
Hb (g/l) Mean  130.9 (126.1 – 135.7) 133.4 (126.7 – 140.1) 0.521 
HbA1c % Median   5.9 (5.8 – 6.0) 8.2 (7.2 – 9.2) <0.001 
SBP (mmHg) Mean  124.0 (119.5 – 128.6) 134.5 (126.7 – 142.4) 0.014 
DBP (mmHg) Mean  77.3 (74.5 – 80.0) 83.1 (79.3 – 86.8) 0.014 
Follow up period (Days) 
Median 
215.5 (198.2 – 232.8) 213.5 (185.4 – 241.6) 0.921 
Initial serology (Titre) 
Median 
0.57 (0.37 – 0.77) 0.87 (0.68 – 1.05) 0.244 
Days between 1st and 2nd 
dose 
19.5 (15.6 – 23.4) 16.0 (12.1 – 19.9) 0.091 
ELISA    
 Post-treatment ≥0.30 (%) 31.7 (20.3 – 45.0) 50.0 (31.9 – 68.1) 0.085 
 Post-treatment ratio 
≥0.60 
25.0 (14.4 – 38.4) 29.0 (14.2 – 48.0) 0.683 
Pre-treatment >0.40 Post 
≥0.40 
16.7 (8.3 – 28.5) 28.1 (13.7 – 46.7) 0.196 
Eosinophilia (%) 54.5 (40.6 – 68.0) 71.9 (53.3 – 86.3) 0.789 
aIndependent samples t-tests for continuous variables, Chi-squared tests for categorical variables, Mann-
Whitney U-test for skewed continuous variables 
 
 
 
  
 43 
 
 
Figure 3.1 Percentage of diabetic and non-diabetic patients achieving a post-treatment titre of <0.30, with 
95% confidence intervals. 
 
 
 
Table 3.3 Outcomes for positive cases by diabetes status after adjusting for age, sex, initial 
titre, follow up period, days between first and second dose and eosinophilia. 
 
Risk ratio 
(RR) 95% CI for RR Sig.a 
ELISA    
Post-treatment ≥0.30 (%) 1.811 1.076 – 3.048 0.025 
Post-treatment ratio ≥0.60 1.482 0.698 – 3.147 0.306 
Pre-treatment >0.40 Post ≥0.40 3.848 1.478 – 10.019 0.006 
aBased on log binomial generalized linear model. 
 
3.2.9 Discussion 
This study confirms the efficacy of ivermectin treatment for strongyloides infection in the 
setting of an Australian Aboriginal community, although the overall failure rate for treatment 
is higher than in some previous studies.78 The use of serology rather than direct 
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microbiological examination for follow up, may in part explain this apparent lower efficacy, 
as it has been noted that the low sensitivity of microbiological tests tend to overestimate the 
efficacy of treatment.29 79  
Reliance upon serology alone for diagnosis, rather than traditional microbiological techniques 
could be perceived as a potential weakness of this study, as it is likely that microscopy alone 
is capable of delivering a specificity of 100%. There is increasing evidence however that 
serology is adequate for diagnosis, sero-surveys and follow up of treatment in this 
condition.25 , and serology may be superior to microscopy in assessing response to treatment 
given the very low sensitivity of microbiological techniques.  
The high proportion of patients with T2DM in this study (51%) could also be a contributing 
factor, given that T2DM is here demonstrated to be a risk factor for treatment failure. The 
low rate of sero-conversion in “equivocal” patients suggests a low incidence of new 
infections in the community, and therefore that the apparent treatment failures are unlikely to 
represent subsequent reinfections. 
Most notably this study finds that pre-existing T2DM is an independent risk factor for 
treatment failure when adjusted for age sex, BMI, initial titre, time between treatments, 
eosinophilia and duration of follow up.  
There are several plausible explanations for the effect of T2DM on treatment outcome. 
Firstly, the possibility exists that drug interactions between T2DM medications and 
ivermectin, and the pharmacokinetics of ivermectin, may have some impact on treatment 
failure rates. The most commonly used diabetic medications in this study were gliclazide and 
metformin. There are no established interactions between gliclazide and ivermectin, and their 
metabolic pathways suggest that an interaction is unlikely. 80 81  
However, poor absorption is known to be a problem with oral ivermectin. [7] 
Hyperinsulinaemia in itself is known to slow gastric emptying 82 and metformin can produce 
gastric side effects including loose bowel actions. It is therefore plausible that impaired 
absorption of ivermectin in diabetic patients taking metformin is a factor in the observed 
association. 
It is also feasible that the altered gut biota known to occur in T2DM patients 41could 
influence the absorption of ivermectin. 
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The complex nature of the interaction between helminth infections and T2DM could mean 
that the nature of the worm infections found in diabetic patients is different. As has been 
demonstrated elsewhere, helminth infections can in themselves affect glucose metabolism 
through a process of immunomodulation 8 and data obtained from this community has 
confirmed a strong negative relationship between S. stercoralis infection and T2DM77 
Consequent to this, it has been suggested that the infections detected in T2DM patients were 
more likely to represent relatively recent infections (contracted after the onset of T2DM) 
whereas the infections in non-diabetics were more likely to represent chronic, well-adapted 
infections with a modified Th2 reaction established in the host. 77 It is known that worm 
numbers are likely to be higher in early infections and to fall to lower numbers in chronic 
infections. 13 The higher treatment failure rate in patients with T2DM could therefore be due 
to a higher average worm burden.  
Ivermectin exerts its effect by paralyzing the adult worms, leading to subsequent worm death, 
and has little effect on the worm larvae.  It may be that relatively early infections in patients 
with T2DM involve higher numbers of auto-infective larvae and that the persistence of these 
larvae, with the subsequent re-establishment of a patent infection, is responsible for the 
higher treatment failure. 
As is well known, T2DM has been implicated in having a negative effect on both the 
frequency and outcome of various infections in human beings, through a variety of proposed 
mechanisms83, 84 and it may be that the observed association simply represents another 
example of this process. Though this effect has not to date been described in helminth 
infections, case histories have been published describing strongyloides hyper-infection 
syndrome in patients where the only known risk factor was T2DM, suggesting that diabetes 
can play some role in impairing the immune response to this infection.22 The fact that 
treatment failure was found to be only weakly associated with HbA1C suggests that glycemic 
control in itself may not be the main or only factor at play. 
Some laboratory evidence exists to suggest that the immune response to helminth infections 
in patients with T2DM may play a role. A recent paper56 has explored the relationship 
between the adipokine resistin, and multiple helminth infections. The authors found that 
human resistin was both up-regulated in the period after helminth infection, and that this 
increased level of resistin was associated with an enhanced Th1 immune response, increased 
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worm burden and impaired parasite clearance. They conclude that resistin could have 
significant implications for the outcome of helminth disease in humans and that increased 
resistin expression could be predictive of impaired immunity to helminths. 
This clearly has implications for individuals with T2DM, as resistin levels have been 
measured in relation to obesity, T2DM and the metabolic syndrome, and are known to be 
variably increased in these conditions. 85 It may be therefore that the observation that T2DM 
is a predictor of treatment failure in S. stercoralis infection reflects once again the presence 
of a complex and intimate relationship between this helminth infection, the human immune 
response, and metabolic illnesses such as T2DM.  
3.2.10 Conclusion 
This study supports the use of ivermectin for the treatment of Strongyloides stercoralis 
infection in an Aboriginal community where the disease is endemic. The association of 
T2DM with treatment failure in this community suggests that further investigation into the 
efficacy of ivermectin in this group is warranted. A plausible mechanism to explain this 
observation involving the adipokine resistin has been described, and further study into the 
complex relationship between helminth infection, immunity and metabolic disease would be 
of value. 
Regardless of the mechanism responsible, this study suggests that clinicians should be 
vigilant when treating T2DM patients for strongyloides infection, ensuring an optimal 
treatment regimen and careful follow up for these individuals. 
3.2.11 Acknowledgments  
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Chapter 4 Strongyloides, T2DM and Eosinophilia in an Aboriginal 
Community 
4.1 Introduction 
As well as characterizing the relationship between T2DM and S. stercoralis infection, the 
data obtained in the initial phase of this study enables assessment of the occurrence and 
extent of peripheral eosinophilia in strongyloides patients. These data are of interest for two 
reasons. Firstly, the scientific and laboratory studies that precede this study suggest that 
eosinophilia may be central to any immuno-metabolic effect that strongyloides infection may 
have in reducing the prevalence of T2DM8, 9. In addition to this, a clinical study that looked 
at the association between eosinophilia and metabolic disease in China found a negative 
association86. From a clinical point of view, eosinophilia has been suggested as a suitable 
clinical indicator of strongyloides infection, with varying degrees of reliability reported 
depending on the setting and the diagnostic tests employed87, 88, 89.  
Helminth infections are known to induce a Th2 weighted immune response which is 
characterized by increased levels of IL5, producing eosinophilia, high levels of IgE and IgG, 
and contributing to inflammation and worm killing. It is also recognized however, that in 
chronic infections helminths are capable of inducing a modified Th2 weighted response, 
associated with lower levels of IL5, diminished eosinophilia, reduced levels of IgE, a 
predominance of IgG4. In addition, chronic infection can result in maintenance of 
alternatively activated macrophages in peripheral tissues via an IL4 and IL13 dependent 
mechanism, with subsequent effects on insulin sensitivity in peripheral tissues9, 70. The 
sensitivity and specificity of eosinophilia as an indicator of strongyloides infection could 
therefore be expected to depend upon the chronicity of infection, and could also be expected 
to reflect the presence or otherwise of insulin resistance and T2DM. 
 For clinicians practicing in remote locations in Australia, where serological testing may be 
relatively difficult to obtain, eosinophilia is often used as a “proxy test” for helminth 
infection. Whether this is a reasonable approach that could be supported by evidence is not 
known. While studies in migrant and non-endemic populations have produced disparate 
results, such an analysis has not been attempted in an endemic population in Australia. Data 
for this paper were collected in 2013 and 2014, and published in 2016. 
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4.2 Strongyloides stercoralis, Eosinophilia, And Type 2 Diabetes Mellitus: the 
Predictive Value of Eosinophilia in the Diagnosis of S. stercoralis Infection 
in an Endemic Community 
Summary: This paper examines the relationship between Strongyloides stercoralis infection 
and eosinophilia in an endemic community, and suggests that eosinophilia is not a reliable 
screening test for excluding S. stercoralis infection in this setting. The relationship between 
T2DM, strongyloides infection and eosinophilia is elaborated. 
 
Abstract 
Background 
This study examines the predictive value of eosinophilia for Strongyloides stercoralis 
infection, as measured by ELISA testing, in an endemic community. In remote communities, 
eosinophilia is frequently used as a proxy test for the presence of helminth infections. Past 
studies of eosinophilia and strongyloides infection have been conducted in specific groups 
such as immigrants and refugees, or in sub-populations of non-endemic communities, rather 
than in endemic communities. 
Methods 
We conducted a cross sectional study of the relationship between eosinophilia and 
strongyloides ELISA serology, as part of a study into the relationship between S. stercoralis 
infection and type 2 diabetes mellitus (T2DM) in an Indigenous community in northern 
Australia. 
Results 
Two hundred and thirty-nine adults had their eosinophil count and S. stercoralis ELISA 
serology measured in 2012 and 2013, along with other biometric and metabolic data. 
Eosinophilia was found to have a relatively poor sensitivity (60.9%), specificity (71.1%), 
positive predictive value (54.6%), and negative predictive value (76.1%) for S. stercoralis 
ELISA positivity in this group. There was however, a more constant relationship between 
eosinophilia and S. stercoralis ELISA positivity in patients with T2DM (negative predictive 
value 87.5%). 
Conclusion 
This study suggests that the presence or absence of eosinophilia is not an adequate proxy test 
for S. stercoralis infection in a community where the infection is prevalent, and that the 
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association between eosinophilia and S. stercoralis ELISA positivity is more constant in 
patients with T2DM. 
 
4.2.1 Introduction 
Infection with the soil-transmitted helminth Strongyloides stercoralis is endemic in many of 
the Indigenous communities of northern Australia, with prevalence of up to 41% recorded in 
some locations.77 
Direct microbiological tests to diagnose the infection are often impractical in these settings as 
multiple fresh fecal samples are required, and sensitivity is low even in ideal circumstances.  
The use of ELISA serology in the diagnosis of strongyloides infection and in conducting 
prevalence surveys has, in the past, been contentious. Uncertainties exist over the meaning of 
positive ELISA results, what level of ELISA test should be considered positive, and whether 
antibodies persevere after the resolution of infection. In addition, cross reactivity with other 
helminth infections was considered to be a problem, particularly with earlier versions of the 
test. Recent studies however suggest that the use of an ELISA test to detect antibodies to the 
worm is both sensitive and specific enough to diagnose the infection and determine the 
success of treatment, and its use is now widespread in clinical practice.24, 25, 26 This test 
however, is currently not available in a point of care format, and therefore entails transport of 
specimens to central laboratories with significant delays in diagnosis and treatment for 
patients in remote locations. 
Eosinophilia is a common, but not uniform, finding in S. stercoralis infection and is thought 
to be more marked in earlier infections, becoming less pronounced and more variable in 
chronic cases.73 Several studies have addressed the relationship between eosinophilia and 
strongyloides infection in the context of patient screening, but these have been conducted in 
migrant and traveler populations, or in sub-populations of non-endemic societies 87, 88, 89, 90, 91, 
92, 93, and have often not addressed the prevalence of strongyloides in patients without 
eosinophilia. 
Infections that are endemic to northern Australia, and that are known to produce eosinophilia 
include Trichuris trichuria, hookworm species, Hymenolepis nana, Toxocara canis, Giardia 
duodenalis and Strongyloides stercoralis94, as well as ectoparasites such as Sarcoptes scabiei, 
resulting in eosinophilia being a common finding in this region.  
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As part of a study conducted into the relationship between type 2 diabetes mellitus (T2DM) 
and S. stercoralis infection, we examined the prevalence of eosinophilia in relation to 
strongyloides infection, as measured by ELISA serology, in an Aboriginal community. Data 
from this study demonstrated a negative relationship between S. stercoralis infection and 
T2DM77, and has suggested that T2DM is a predictor of treatment failure in this setting.95 
Eosinophilia is thought to be central to the process by which helminth infections can affect 
the metabolic status of infected subjects through a process of immunomodulation.8  
This study provides, for the first time, data on the predictive value of eosinophilia in the 
diagnosis of S. stercoralis infection in an endemic community and analyses this in the context 
of T2DM. 
4.2.2 Materials and methods 
The study was conducted in three related Indigenous communities, located within a 100km 
radius in the Tanami desert region of Western Australia. Opportunistic testing for, and 
treatment of S. stercoralis was commenced in these communities in 2012 according to the 
best practice guidelines of the Australian Strongyloides working group.31 
S. stercoralis ELISA testing was ordered, often in conjunction with other routine laboratory 
investigations. Testing was performed by Pathwest Laboratory in Perth Western Australia, 
using the commercial strongyloides IgG ELISA (DRG laboratory). The reference values, in 
units of absorbance, for this test were as follows: Less than 0.2 –Negative; 0.2 to 0.4 –
Equivocal; Greater than 0.4 –Positive. However, as was noted by the laboratory, these ranges 
were developed in a metropolitan population where the prevalence of S. stercoralis was very 
low (manufacturers information). In order to reduce the possibility of false negative results it 
was decided to employ a modified range. All values greater than or equal to 0.30 were 
considered positive and treated. All values less than 0.30 including those less than 0.20 were 
considered equivocal and were re-tested after a period of 6 months, in order to ascertain the 
rate of sero-conversion (and presumably therefore new infections) in this group. Only 3 sero-
conversions were found in this time, and the analysis for this study was performed using the 
results of the initial testing only. 
Data was extracted including the age, sex, date of testing, S. stercoralis ELISA titre 
haemoglobin, total eosinophil count, percentage eosinophilia, height, weight, calculated Body 
Mass Index (BMI), diabetic status and HbA1C Triglyceride level, HDL and total cholesterol. 
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The study population for this study was identical to that in our two previous studies in this 
community.77, 95 
Eosinophilia was defined as a total eosinophil count of 0.50 x109/L or greater. 
Diabetes was defined in this group as an HbA1C reading of 6.5% or greater, or a random 
blood glucose of more than 11.1 mmol/l, or a fasting blood glucose of more than 7.0 mmol/l, 
either at the time of testing, or in the past in patients already receiving treatment for diabetes. 
4.2.3 Ethical approval 
The protocol for this study was approved in principle by the Kimberley Aboriginal Health 
Planning Forum. All participant were 21 years of age or older. As no investigations or 
treatments apart from those required for best clinical practice were being performed, and 
literacy levels are very low in the study population, verbal consent was considered 
appropriate. Verbal consent was obtained from all participants and recorded electronically. 
Formal ethical approval was granted by the Western Australian Aboriginal Health Ethics 
Committee (HREC:515)  
4.2.4 Statistical analysis 
Descriptive statistics, including means, medians, percentages and their respective 95% 
Confidence Intervals were used to analyze the demographic and clinical characteristics of 
participants. The accuracy of eosinophilia (≥0.50) as a measure of S. stercoralis status (E-
titre ≥ .30) was evaluated using sensitivity and specificity measures. To account for the high 
prevalence of S. stercoralis, the Positive Predictive Value (PPV) and Negative Predictive 
Value (NPV) for the ≥.50 eosinophilia cut off were also calculated. These diagnostic test 
evaluations were also undertaken separately for participants with and without diabetes.  
Four logistic regression analyses were undertaken to examine the association between 
diabetes status and the sensitivity, specificity, PPV and NPV of eosinophilia as measure of  
S. stercoralis. As a first step, dichotomous variables were created to flag participants that 
were true positive cases (eosinophilia ≥.50 and E-titre≥.30) or true negative cases 
(eosinophilia <.50 and E-titre<.30).  
The sensitivity regression was the odds of diabetic participants with S. stercoralis having a 
positive eosinophilia diagnosis (true positive) compared to the odds of the same true positive 
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diagnosis among non-diabetic participants. The specificity regression was the odds of a true 
negative diagnosis by these diabetes groups.  
Analysis of PPV was the odds of a true positive diagnosis among diabetic patients with a 
positive eosinophilia compared to non-diabetic patients. The NPV regression was the odds of 
true negative diagnosis among those with a negative eosinophilia result, again by diabetes 
status.  
All regression analyses were also adjusted for sex, age, BMI and previous anthelminthic 
treatment with albendazole. Cases with missing values on any of these variables were 
dropped from the adjusted modeling. A 5% significance level was used for all statistical tests 
and all analyses were undertaken using STATA v13. (StataCorp. 2013. Stata Statistical 
Software: Release 13. College Station, TX: StataCorp LP.) 
4.2.5 Results 
A total of 259 patients were screened, with 92 (35.5%: 95% CI 29.9 – 41.6%) cases of 
strongyloides infection, as indicated by ELISA serology of ≥ 0.30, diagnosed. Eosinophil 
counts however, were available for only 239 patients, with the missing values being due to 
specimen degradation during transport. Of the 20 degraded specimens 5 were positive for  
S. stercoralis by ELISA testing and 7 had T2DM. Table 4.1 details the clinical characteristics 
of the 239 patients with both ELISA testing results and eosinophil counts.  
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Table 4.1 Prevalence of Eosinophilia (≥0.5) and S. stercoralis (E-titre ≥0.4) by diabetes status. 
Diabetes 
status Eosinophils measure 
S. stercoralis serology status (ELISA titre)   
Positive (% E-titre ≥0.4) Negative (% E-titre <0.4) Total 
n % n % N % 
Non-diabetic 45 39.1 70 60.9 115 100.0 
  Eosinophilia (≥0.5) 24 53.3 21 46.7 45 100.0 
  Non-eosinophilia (<0.5) 21 30.0 49 70.0 70 100.0 
                
Diabetic   26 21.0 98 79.0 124 100.0 
  Eosinophilia (≥0.5) 20 38.5 32 61.5 52 100.0 
  Non-eosinophilia (<0.5) 6 8.3 66 91.7 72 100.0 
                
Total   71 29.7 168 70.3 239 100.0 
  Eosinophilia (≥0.5) 44 45.4 53 54.6 97 100.0 
  Non-eosinophilia (<0.5) 27 19.0 115 81.0 142 100.0 
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Table 4.2 shows that 97 patients had eosinophilia, giving an overall prevalence of 
40.6% (95% CI 34.5 – 47.0%). In the infected patients, the prevalence was 60.9% 
(50.1 – 70.7%). The prevalence of eosinophilia was similar in diabetic compared to 
non-diabetic subjects, (41.9% (95% CI 33.5 – 50.9%) and 39.1% (95%CI 30.5 – 
48.5%) respectively, OR 1.12 95%CI 0.67-1.88, p=0.659) while the prevalence of 
eosinophilia was higher in infected diabetics compared to infected non-diabetics, 
although this difference did not reach statistical significance (71.0% 95%CI (51.8 – 
84.8%) and 55.4% (95% CI 41.9 – 68.1%) respectively OR 1.97, 95% CI 0.77 – 5.03, 
p=0.156). 
A quarter (25.0%) of the diabetic patients had a positive S. stercoralis ELISA test 
compared to almost half of the non-diabetic patients (48.7%).  Eosinophilia as a test 
for S. stercoralis had a sensitivity of 60.9% and a specificity of 71.1% (Table 4.3). 
Eosinophilia had an overall PPV of 54.6% and a NPV of 76.1%.  The NPV of 
eosinophilia was higher in diabetic patients (87.5%, 95%CI 77.6 - 94.1) compared to 
non-diabetic patients (64.3%, 95%CI 51.9 – 75.4).  
As the ELISA cut off level of 0.30 units was used in this study for purely clinical 
reasons, the analysis was repeated using the conventional cut off of 0.40 units 
(Appendix 2 Tables 1-3) and again using a higher cut-off of 0.50 for the purposes of 
comparison. The NPV of eosinophilia remained high for both cut off levels (81.0% 
for ≥ 0.40 and 86.6% for ≥ 0.50) and the differences between diabetic and non-
diabetic patients remained comparable.  
Logistic regression (Table 4.4) showed that among the 97 patients with eosinophilia, 
the odds of having a positive S. stercoralis ELISA test (PPV) were 67% lower among 
diabetic patients compared to those without diabetes (OR=0.33, 95%CI 0.14–0.77, 
p=0.010). This difference remained after adjusting for age, sex, weight, BMI and past 
treatment with anthelminthic drugs (n=95, OR=0.30, 95%CI 0.11–0.81, p=0.018). In 
comparison, diabetics without eosinophilia were almost four times more likely to also 
have a negative S. stercoralis ELISA test (NPV), compared to non-diabetic patients 
without eosinophilia (n=142, OR=3.89, 95%CI 1.66–9.12, p=0.002). This difference 
remained after adjustment, although 14 patients were excluded due to missing values 
on potential confounding variables (n=128, OR=4.51, 95%CI 1.73–11.76, p=0.002). 
 56 
Table 4.2 Accuracy of Eosinophilia (≥0.5) as a measure of S. stercoralis status 
determined by serology (E-titre ≥0.4). 
Parameters 
Non-diabetic 
(n=115) 
Diabetic 
(n=124) 
Total 
(n=239) 
  n (%) n (%) n (%) 
True negatives 49 (42.6) 66 (53.2) 115 (48.1) 
False positives 21 (18.3) 32 (25.8) 53 (22.2) 
True positives 24 (20.9) 20 (16.1) 44 (18.4) 
False negatives 21 (18.3) 6 (4.8) 27 (11.3) 
              
  (%) (95% CI) (%) (95% CI) (%) (95% CI) 
Sensitivity (53.3) (37.9, 68.3) (76.9) (56.4, 91) (62.0) 
(49.7, 
73.2) 
Specificity (70.0) (57.9, 80.4) (67.3) 
(57.1, 
76.5) (68.5) 
(60.8, 
75.4) 
Positive 
predictive value (53.3) (37.9, 68.3) (38.5) (25.3, 53) (45.4) 
(35.2, 
55.8) 
Negative 
predictive value (70.0) (57.9, 80.4) (91.7) 
(82.7, 
96.9) (81.0) 
(73.6, 
87.1) 
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Table 4.3 Regression analyses of sensitivity, specificity, positive predictive value and 
negative predictive value by diabetes status. 
Analysis 
Diabetes 
status 
Unadjusted odds ratio Adjusted odds ratio† 
n OR (95% CI) n OR (95% CI) 
Analysis of sensitivity 71     66     
  Non-diabetic 45 1.00   41 1.00   
  Diabetic 26 2.92 (0.99, 8.62) 25 3.68 (1.05,12.91)* 
                
Analysis of specificity 168     157     
  Non-diabetic 70 1.00   66 1.00   
  Diabetic 98 0.88 (0.46, 1.72) 91 0.99 (0.47, 2.06) 
                
Analysis of positive 
predictive value 97     95     
  Non-diabetic 45 1.00   43 1.00   
  Diabetic 52 0.55 (0.24, 1.23) 52 0.53 (0.20, 1.39) 
                
Analysis of negative 
predictive value 142     128     
  Non-diabetic 70 1.00   64 1.00   
  Diabetic 72 4.71 (1.77, 12.56)* 64 5.50 (1.83, 16.56)* 
* p<0.05 
† Adjusted for sex, age, BMI and past antibiotic treatment 
Eosinophilia (≥0.5) and S. stercoralis (E-titre ≥0.4) 
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Table 4.4 Logistic regression analyses of sensitivity, specificity, positive predictive 
value and negative predictive value by diabetes status. 
Analysis 
Diabetes 
status 
Unadjusted odds ratio Adjusted odds ratio† 
n OR (95% CI) n OR (95% CI) 
Analysis of sensitivity 87     82     
  Non-diabetic 56 1.00   52 1.00   
  Diabetic 31 1.97 (0.77, 5.03) 30 2.07 (0.73, 5.84) 
                
Analysis of specificity 152     141     
  Non-diabetic 59 1.00   55 1.00   
  Diabetic 93 0.65 (0.31, 1.37) 86 0.74 (0.33, 1.66) 
                
Analysis of positive 
predictive value 
97     95     
  Non-diabetic 45 1.00   43 1.00   
  Diabetic 52 0.33 (0.14, 0.77)* 52 0.30 (0.11, 0.81)* 
                
Analysis of negative 
predictive value 
142     128     
  Non-diabetic 70 1.00   64 1.00   
  Diabetic 72 3.89 (1.66, 9.12)* 64 4.51 (1.73, 11.76)* 
* p<0.05 
† Adjusted for sex, age, BMI and past antibiotic treatment 
 
 
4.2.6 Discussion 
This study suggests that eosinophilia alone cannot be used to infer the presence of 
Strongyloides infection in patients from Indigenous communities where the condition 
is endemic. This is perhaps not a surprising finding given the large number of other 
parasitic infections that are present in these communities and capable of causing 
eosinophilia.  
More notably however, was the relatively low NPV of eosinophilia, suggesting that 
the absence of eosinophilia does not reliably rule out the diagnosis of Strongyloides 
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infection in this setting. In fact, in this study almost a quarter of patients without 
eosinophilia had positive Strongyloides ELISA serology. This is of relevance to 
clinicians because, in a remote setting, the absence of eosinophilia is often used as a 
proxy test to imply the absence of parasitic infection. This study suggests that such a 
practice would not be safe as a means to exclude Strongyloides infection, particularly 
in situations where the patient faces immunosuppression or chemotherapy. 
Immunosuppression and or steroid therapy in the presence of undiagnosed 
Strongyloides infection can lead to hyperinfection syndrome, often with fatal 
consequences.22 
The findings are similar to those of Naidu et. al. in their survey of refugee populations 
in Canada, where they are also at pains to point out that the absence of eosinophilia 
should not be used to infer the absence of Strongyloides infection.88 They are at odds 
however with a survey of farm workers carried out in southern Spain where the 
results suggested that eosinophilia had a specificity of 93.1% and sensitivity of 
93.5%, and the authors recommended public health screening for strongyloidiasis 
using eosinophilia.93 Clearly the situation in this community is quite different, with a 
low level of transmission overall and the absence of other significant parasitic 
infections. This disparity can also be explained in part by differences in the method of 
diagnosis employed. The Spanish study used microbiological examination of stool 
specimens for diagnosis, a method that is known to have a low sensitivity, and to be 
influenced by the worm burden and subsequent numbers of larvae shed in the 
faeces.24 Eosinophilia is known to be more common in early or acute Strongyloides 
infections, when worm burden and larval counts are highest, and to decline and 
become more variable in chronic infection presumably through the mechanism of 
parasite induced immunomodulation in the host.13, 73 Use of fecal testing for diagnosis 
would therefore tend to select earlier infections, with higher worm counts and 
therefore higher rates of eosinophilia, while ELISA testing would detect more chronic 
infections where immunomodulation had resulted in more variable eosinophilia. 
This study found that the prevalence of eosinophilia in diabetic subjects was no 
different to that in non-diabetic. This is at odds with the findings of a much larger 
cross-sectional study performed in China that demonstrated a negative relationship 
between eosinophilia and insulin resistance and T2DM.86 The Chinese study, 
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however, was conducted in a population where both helminth infection and 
eosinophilia are less prevalent, and where other, non-infectious causes of eosinophilia 
are likely to be more common. 
Data from this community published elsewhere demonstrates a negative relationship 
between Strongyloides infection and T2DM.77 It is postulated that this effect is again 
due to parasite-induced immunomodulation affecting the hosts metabolic system in 
chronic infections and resulting in increased insulin sensitivity. Laboratory evidence 
suggests that eosinophilic infiltration of adipose tissue due to helminth infection 
promotes the presence of alternatively activated macrophages, which in turn act to 
increase insulin sensitivity.8 
This study however, showed a higher prevalence of eosinophilia in ELISA positive 
diabetics and demonstrates that the absence of eosinophilia in diabetic subjects is 
more closely linked with the absence of Strongyloides antibodies. This might be 
explained if the diabetic group contains a greater proportion of acute or recent 
infections, resulting in a more marked eosinophilia, as opposed to chronic and 
immune-modulated infections, where eosinophilia is less pronounced and where the 
past eosinophilic infiltration of adipose tissue has contributed to a lower prevalence of 
T2DM.  
It is equally plausible that T2DM itself is responsible for the higher rate of 
eosinophilia. A recently published paper looked at the relationship between the 
human adipokine resistin and multiple helminth infections. It found that higher 
resistin levels were associated with a more pronounced inflammatory response, a 
higher worm burden and reduced worm clearance.56 T2DM along with obesity and 
metabolic syndrome has been variably linked with elevated levels of resistin.85 In 
addition, data from this study published elsewhere found that T2DM was associated 
with treatment failure in Strongyloides infection suggesting that the immune response 
may be altered in diabetics.95  
Perceived weaknesses of this study may be that it relies on ELISA serology alone for 
diagnosis, rather than microscopy which is the most specific test, however we feel this 
is outweighed by the superior sensitivity of the serological test. Clearly the numbers 
involved in this study are small, and further larger studies may be of benefit.  
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In addition, no distinction was made between mild, moderate and severe eosinophilia, 
with the single cut off point of 0.5 x109 /l being used. It may be that employing a 
lower threshold for eosinophilia might improve the negative predictive value of the 
test. 
This study supports the use of ELISA testing for Strongyloides infection as a 
screening test for patients in endemic Aboriginal communities regardless of their 
eosinophilia status, and suggests the practice of presuming the absence of infection in 
patients without eosinophilia is not a safe one. It may be that the absence of 
eosinophilia might be of some use in the decision to screen or treat for 
strongyloidiasis in the diabetic population in this community.  
Further studies would be needed to assess whether this is the case in other settings 
where the disease is endemic and to further examine the link between eosinophilia 
and T2DM. 
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Chapter 5 Outcomes of Treatment for Strongyloides stercoralis in an 
Endemic Community: Control of Infection 
5.1 Introduction 
Follow up of this cohort of patients has two main objectives. Central to this thesis is 
the aim of further characterizing the relationship between S. stercoralis infection and 
T2DM, and this will be discussed in Chapter six. As has been noted however, the 
study design also enables assessment of the long-term effectiveness of ivermectin and 
its use in a “case finding and treatment” strategy for the control of strongyloides in 
this community. This is of considerable interest to the many clinicians who are 
concerned with the control and elimination of S. stercoralis infection in Aboriginal 
Australia, and potentially in endemic communities world-wide. It is also central to the 
main concerns of this thesis, as attempts to control this infection must inevitably be 
weighed up against potential adverse metabolic effects in the treated populations. 
 One of the unique contributions made by this thesis is the duration of follow up that 
was achieved for this cohort. A time scale of three years was chosen mainly in order 
to allow the emergence of any effects on metabolic outcomes to become apparent, 
however, this also enabled a relatively long term follow up of the success of 
treatment. As stated previously, prior studies had been characterized by relatively 
short time scales, usually 6 to 12 months, designed to test the efficacy of treatment 
rather than the effect on disease prevalence, and had often suffered from a high rate of 
loss to follow up.  The protocol for this study was unique in that it employed a “case 
finding and treatment” approach to the treatment of strongyloides infection, and then 
examined the outcomes after 3 years for patients who continued to live in an endemic 
community in the absence of any further attempts at screening or treatment, and in the 
absence of any environmental control program. It therefore provides evidence as to 
the effectiveness of such a treatment strategy in sustainably reducing the prevalence 
of infection in an adult population over the medium to long term. A case finding and 
treatment strategy stands in contrast to “mass drug administration” (MDA) strategies 
which have been suggested for affected communities. A recent study published in 
Australia demonstrated that MDA for strongyloides infection was successful in 
reducing the prevalence of infection over a limited time period, but did not eliminate 
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the infection, and had no effect on clinical symptoms96. If it could be demonstrated 
that a case finding and treatment strategy was equally effective in controlling disease 
prevalence, then the issue of possible adverse metabolic side effects becomes 
clinically important. A public health measure such as an MDA does not allow for 
consideration of an individual’s metabolic status in the way that a case finding and 
treatment strategy does. Potential adverse metabolic consequences of treatment, 
which could be allowed for clinically in a case finding and treatment strategy, could 
only be balanced by further public health measures in an MDA model. 
Collection of the data in this study occurred in 2014 and 2016, and the results were 
published in 2017 
Hays R, Esterman A, McDermott R, 2017. Control of chronic Strongyloides 
stercoralis infection in an endemic community may be possible by 
pharmacological means alone: results of a three-year cohort study. PLoS 
neglected tropical diseases. Jul 31;11(7): e0005825. 
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5.2  Control of Chronic Strongyloides stercoralis Infection in an Endemic 
Community may be Possible by Pharmacological Means Alone: 
Results of a Three-Year Cohort Study 
5.2.1 Abstract 
Objectives: To assess the effect of treatment with ivermectin on the prevalence of  
S. stercoralis infection in an Australian Aboriginal population over a three-year 
period, and to assess the validity of using a lower ELISA cut-off in diagnosis. 
Methods: A three-year cohort study of 259 adult Australian Aboriginals living in a 
remote community in northern Australia. S stercoralis infection was diagnosed using 
commercial ELISA testing, and employed a lower threshold for treatment than that 
recommended. Follow up was conducted at 6 months and 3 years following 
ivermectin treatment. 
Findings: Treatment with ivermectin was highly effective and resulted in a sustained 
fall in the prevalence of infection in the study group (Initial prevalence 35.3%, 3-year 
prevalence 5.8%, McNemar’s chi2 =56.5, p<0.001). Results of treatment suggested 
use of a lower ELISA threshold for treatment was valid in this setting. Follow up 
identified a small group of subjects with persistently positive ELISA serology despite 
repeated treatment. 
Interpretation: Control of S. stercoralis infection in this cohort appears to be feasible 
using pharmacological treatment alone.  
5.2.2 Author summary 
Infection with the worm Strongyloides stercoralis is common throughout the 
developing world, and in some resource poor communities living within developed 
societies, such as the Aboriginal communities of northern Australia. It is generally 
agreed that reliable diagnosis of this infection is possible by blood tests, and that the 
medication ivermectin represents the best available treatment, however questions 
remain over how to best control and eliminate the infection in areas where it is 
common.  
Strongyloides infections may be asymptomatic, and may persist indefinitely without 
the need for re-infection. The worm is transmitted by contact with contaminated soil. 
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Suggested strategies for control have therefore included mass administration of 
ivermectin in affected areas, and environmental measures to prevent the 
contamination of soil. 
In this study, we follow up a group of subjects living in an endemic community three 
years after they were tested and treated for strongyloides infection. We find a 
persisting low prevalence of infection in this group in the absence of any 
environmental changes or further treatment, suggesting that control of the infection in 
this community might be achieved through simple case finding and treatment alone. 
In addition, we suggest the use of a lower cut-off value for serological testing in these 
communities, in order to avoid missing cases of infection. 
5.2.3 Introduction 
Infection with the soil-transmitted helminth (STH) Strongyloides stercoralis is 
common in both the developing world, and in underprivileged communities in 
developed countries. Prevalence is frequently estimated at 30- 100 million cases 
world-wide, but due to difficulties with diagnosis, the frequent absence of symptoms 
in chronic cases, and the lack of extensive screening for the infection, this may be an 
under-estimate 23. The major medical impact of infection is thought to be the 
occurrence of strongyloides hyperinfection syndrome, which occurs predominantly in 
infected adults who become immunosuppressed, whether by iatrogenic means or 
otherwise 22. 
It is increasingly acknowledged that S. stercoralis infection represents a significant 
public health challenge and that action is required to deal with the problem 12, 
however there is no general agreement as to what these measures should be. Some 
advocate the need for extensive environmental management of the problem to 
interrupt transmission in endemic communities 18, 97. They point out that 
pharmacological treatment can have side effects, cannot prevent re-infection from 
environmental sources of the infection, and that resistance to ivermectin may develop 
with excessive use. Others emphasize the efficacy and safety of treatment with 
ivermectin, and advocate pharmacological control, with possible mass drug 
administration (MDA) in communities that have a high prevalence of infection in 
accordance with programs currently employed to control other soil transmitted 
helminth and vector borne nematode infections 23. They point out that free-living 
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forms of the parasite are relatively transient, human beings constitute the major 
reservoir of infection, and while some resistance has been noted in veterinary settings, 
to date there is no evidence of resistance in human infection. Still others have 
advocated a combination of these approaches, employing case finding and treatment 
with ivermectin, in association with public health measures such as improved 
sanitation 98. 
A measure of success has been reported to date, with studies employing both 
approaches reporting positive results in control of the infection. 98, 99 
It should be pointed out that the optimal measures for control of strongyloides 
infection may differ from situation to situation, depending upon local factors such as 
rainfall and vegetation, the importance of agricultural practices in transmission, and 
the presence or otherwise of adequate health infrastructure. Because of the chronic 
nature of this infection and its capacity for sustained auto-infection within individuals, 
it is possible to have a high prevalence of infection both in communities where 
conditions allow for high transmission rates of the infection, and equally in 
communities where transmission is lower, but there are a high number of chronic, 
untreated infections.     
The Aboriginal communities of northern Australia are home to some of the highest 
measured prevalence of this infection, with rates of 30-40% reported 34. 
Oral ivermectin is now accepted as the treatment of choice for this condition, but 
disagreement persists over the need for wide spread testing and elimination of the 
infection. Attention has been drawn to some of the barriers preventing control of 
infection in these communities, including difficulties with diagnosis and lack of 
adequate follow up of treated cases 76. 
Direct parasitological diagnosis of infection and other coprological methods are 
generally not feasible in these isolated communities, and are known to have a low 
sensitivity even when performed under optimal conditions. ELISA testing is now 
generally accepted as being sensitive and specific enough for use in both clinical and 
research settings 23, 26. Concerns over cross reactivity with other helminth infections 
have less relevance in the Australian setting where these infections are not found. In 
practical terms in the Australian setting this equates to testing using one of several 
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commercially available ELISA tests. The reference ranges for these tests were 
developed in relatively low prevalence populations and were intended to prevent false 
positive results in situations where the infection is uncommon. For example, the 
unreferenced product information for one such test (DRG laboratories) advises 
clinicians that normal ranges may need to be interpreted “in the context of local 
settings”. Anecdotally, it is reported that for this reason, clinicians working in 
communities where the infection is known to be endemic frequently treat patients 
whose ELISA results fall under the published range, in an attempt to avoid missing 
infections. To date there have been no attempts to validate this approach, and studies 
of treatment efficacy have mostly been characterized by limited and poor follow up of 
treated cases 34. 
The current study comprises a three year follow up of a cohort of patients tested and 
treated for strongyloides infection in an Aboriginal community in northern Australia 
as part of a study into the relationship between S. stercoralis infection and type 2 
diabetes mellitus 77. It is the first study to examine the long-term outcome for adults 
tested and treated for the infection, who continue to live in an endemic community in 
the absence of any attempt at environmental manipulation.  
Furthermore, as the original cohort was established using a revised (and lower) cut off 
for ELISA positivity, there can now be an attempt to validate the use of a lower 
ELISA threshold for treatment by looking at response to treatment and long-term 
outcomes in these patients. 
5.2.4 Methods 
5.2.4.1 Study population 
The study was conducted in three Aboriginal communities located within a 100km 
radius of each other in the far north Kimberley region of Western Australia. The 
communities are isolated, with the nearest hospital and laboratory services being 
800km away. Prior to the commencement of this study, testing and treatment for  
S. stercoralis infection had not taken place in any systematic manner. 
The cohort comprised 259 adult Aboriginals attending the medical facilities in these 
communities, and was originally established from April 2012 to December 2013 as 
part of a study into the relationship between S. stercoralis infection and type 2 
 68 
diabetes mellitus (T2DM). The protocol for this study has been published 
previously77.  
Patients were offered testing and treatment for S. stercoralis infection on an 
opportunistic basis when attending the clinics. No attempt was made to screen 
patients on the basis of presenting symptoms, as it was felt that there was little 
evidence for the presence of reliable symptoms in chronic strongyloidiasis in an 
endemic setting. Recent results from a study conducted in an Aboriginal community 
would seem to support this 96. Patients who were normally resident outside the 
communities were excluded, as were patients who had received prior treatment with 
ivermectin, without serological testing for S. stercoralis. 
5.2.5 Serological testing for S. stercoralis 
Diagnosis of S. stercoralis infection was established purely through serological means 
as direct parasitological studies would have been logistically difficult in this setting, 
and would likely have lacked sensitivity 25. 
ELISA testing was carried out at a reference laboratory utilizing a commercial  
S. stercoralis ELISA kit (DRG laboratories) that tests for the presence of IgG 
antibodies. All positive results were subsequently tested in parallel and the revised 
value used in analysis.  
The normal ranges (in units of absorbance) provided by the laboratory for this test 
were  
: < 0.20 – Negative 
: 0.20- 0.40 – Equivocal 
: > 0.40 –Positive 
 
These normal ranges were developed in a low prevalence population however. A prior 
survey in the study community had suggested that a prevalence of infection greater 
than 30% was likely 31 and therefore, in order to reduce the possibility of false 
negative results, a modified normal range was employed for diagnosis. All results 
greater than 0.30 were considered as “positive”, and were treated. All results less than 
0.30, including those less than 0.2, were considered “equivocal” from the point of 
view of follow up, and were placed on recall for repeat testing in 6 months. 
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5.2.6 Treatment and follow up 
All patients returning positive results according to the protocol were treated with 2 
doses of ivermectin 0.2mg/kg, given 2 weeks apart under direct observation.  
All 259 patients in the study were then recalled after 6 months for repeat serological 
testing. The results of 6 month testing have been published previously, as part of a 
study into the relationship of treatment outcomes and T2DM 95.  
Any subjects found to be ELISA positive at 6 months were recalled for repeat 
treatment with a single dose of ivermectin 0.2mg/kg. An audit of patient records 
shows that of the 29 subjects who remained ELISA positive at 6 months, 24 received 
an extra dose of ivermectin at this time, while 5 did not.  
Routine follow up of patients was then conducted by the individual clinics. Clinic 
records show that a further 5 subjects received a fourth dose of ivermectin, for 
presumed strongyloides infection, during the subsequent 2½ years.  
All subjects were finally recalled approximately 3 years after initial testing for repeat 
ELISA testing and metabolic assessment. Any subjects found to be ELISA positive at 
this time were treated with a further dose of ivermectin 0.2mg/kg. Three year follow 
up also involved an assessment of the subject’s metabolic status as part of an ongoing 
study into the relationship between strongyloides and T2DM, the results of which will 
be published separately100.  
5.2.6.1 Treatment outcomes 
Treatment outcome in this study was evaluated in two ways. Firstly, “treatment 
success” was defined as a fall in ELISA serology to < 0.30 at follow up. “Treatment 
effect” was defined as a ratio of post treatment ELISA to pre-treatment ELISA of less 
than 0.60.  
As a modified normal range was used in this study to identify positive cases, at follow 
up it was possible to compare two groups; those whose initial serology was above the 
established positive range of ≥ 0.40 (designated “high titre”), and those whose initial 
serology was in the range between ≥ 0.30 and< 0.40 (designated “low titre”) These 
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groups were compared in terms of treatment success and treatment effect on the basis 
that if those in the low titre group represented true infections with S. stercoralis 
(rather than false positives) then treatment outcomes should be similar to those 
achieved in the high titre group. Additionally, outcomes for the two groups were 
compared in terms of the average ELISA serology of both groups at 3 years follow 
up, on the basis that if both groups represented true infections, and both groups were 
treated in the same way, then the two groups should be similar in terms of outcomes 
at 3 years 
5.2.6.2 Assessment of “non-responders” 
During the course of follow up it became apparent that a small number of subjects 
continued to return positive ELISA results after three years of follow up, despite 
repeated treatment with ivermectin (designated “non-responders”). Clearly it is of 
interest as to whether these non-responders represent true treatment failure or re-
infection, or whether they are simply continuing to produce a positive ELISA test in 
the absence of ongoing infection. To aid in the assessment of these subjects, 
additional testing was carried out, including serological testing for HTLV-1 virus, 
serum IgE, FBE, and a multivalent faecal PCR test for S. stercoralis targeting a 101bp 
region of the 18S gene (Western Diagnostic Pathology, Myaree) 101. Molecular testing 
of faeces specimens was employed, as it is logistically easier to achieve from an 
isolated location. Studies suggest that, although still less sensitive than serology, it has 
improved sensitivity over direct parasitological methods[27]. 
5.2.7 Statistical analysis 
McNemar’s chi-square test for correlated proportions was used to compare prevalence 
rates at the different time points. Comparison of mean age and BMI and change in 
eosinophil count between responders and non-responders was undertaken using 
independent samples t-tests. No attempt was made to impute data for those lost to 
follow up. Logistic regression was used to determine differences in outcome for high 
titre and low titre cases.  
5.2.8 Ethics statement  
The protocol for this study was approved by the Kimberley Aboriginal Health 
Planning Forum. Ethical approval for the study was obtained through the Western 
Australian Aboriginal Health Ethics Committee (WAAHEC) in 2014 (HREC 
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Reference 515). All subjects were over 18 years of age and provided informed verbal 
consent. Use of verbal consent was approved by WAAHEC as no additional tests or 
treatments were required other than those dictated by the current best management 
guidelines for this condition, and due to variable rates of literacy in the study 
community. Consent was recorded electronically in the subject’s permanent medical 
record. 
5.2.9 Results 
5.2.9.1 Treatment outcomes 
Demographic data for the 259 patients originally enrolled in the study are given in 
Table 5.1.  
Table 5.1 Demographic data. 
  Not treated Treated Overall Sig. 
  N % N % N % P 
Age <30 18 10.7 17 18.7 35 13.5 0.141 
 30-39 64 38.1 26 28.6 90 34.8  
 40-49 44 26.2 20 22.0 64 24.7  
 50+ 42 25.0 28 30.8 70 27.0  
 Total 168 100.0 91 100.0 259 100.0  
         
Sex Male 69 41.1 37 40.7 106 40.9 0.949 
 Female 99 58.9 54 59.3 153 59.1  
 Total 168 100.0 91 100.0 259 100.0  
 
Successful follow up was achieved in 207 of the original cohort at 3 years, with 52 
subjects lost to follow up as outlined in Figure 5.1. Those lost to follow up were 
similar in terms of infection status (36.5% vs. 35.2%, p=0.85), with a tendency to be 
female (62% vs. 48%; p=0.071). All other baseline comparisons were similar. 
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Figure 5.1 Outcome of follow up at three years. 
Figure 5.2 gives a graphical illustration of the outcome in terms of serology for those 
followed up at 6 months and 3 years. Treatment with ivermectin was highly effective, 
with the prevalence of ELISA positive subjects falling from an initial 35.3% to 13.4% 
(McNemar’s chi2 = 46.6, p<0.001) at 6 months and 5.8% (McNemar’s chi2 = 56.5, 
p<0.001) at 3 years, respectively.  
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*One patient who tested positive to S. stercoralis but left the community prior to treatment, has been 
excluded from analysis. 
Figure 5.2 Treatment outcome at three years.  
Only three new cases were diagnosed in the first 6 months of follow up, with a further 
three in the period up to 3 years. Three cases that had returned to negative at 6 months 
were found to be ELISA positive again at 3 years. It should be noted that it is not 
possible to ascertain whether these three cases represent relapse of existing infection, 
presumably through the process of “auto-infection” that is known to occur in chronic 
strongyloidiasis, or re-infection from environmental sources. The details of these 
subjects are summarized in Table 5.2. 
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Table 5.2 New cases at follow up. 
Subject Age 
Initial 
ELISA 
Six month 
ELISA 
Three year 
ELISA 
Female 53 0.19 0.30^ 0.12* 
Female 43 0.15 0.43^ 0.20* 
Female 30 0.18 0.30^ 0.22* 
Male 43 0.22 - 0.34^ 
Male 69 0.15 0.24 0.33^ 
Female 29 0.14 0.03 0.40^ 
Female 73 0.48^ 0.28 0.37^ 
Female 70 0.51^ 0.29 0.37^ 
Male 43 0.35^ 0.27 0.32^ 
*After treatment at 6 months follow up. - Subject was lost to follow up at 6 months. ^Positive results. 
All new cases at 6 months and 3 years involved only a marginal increase in ELISA, 
with only two cases rising above the accepted positive range of 0.40, and the others 
deemed positive due to the use of a reduced cut-off in this study. Additionally, the 
three cases that “relapsed” after cure at 6 months in fact only dipped marginally 
below the cut-off of 0.30, before returning to marginally above. 
An analysis of treatment outcomes at 6 months with respect to treatment failure has 
been published previously 95. 
 
5.2.9.2 Non-responders 
Of the 12 positive cases at 3-year follow up, 9 represent “treatment failure”, with 
these subjects remaining ELISA positive throughout follow up, despite repeated 
treatment with ivermectin. The details of these subjects are presented in Table 5.3, 
along with the results of the further tests conducted. Comparisons of mean age, BMI 
and eosinophil counts with the subjects who responded to treatment are included. 
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Table 5.3 Details of Non-responders. 
 Age Initial BMI 
Initial 
ELISA 
(abs.) 
Six month  
ELISA 
Final 
ELISA 
Initial 
eosin.(x109) 
Final eosin. 
(x109) HTLV-1  
IgE 
(kU/ml) 
Fecal 
PCR 
1 Male  75 30.37 0.65 0.45 0.45 0.59  0.13 Neg -  * - 
2 Female 58 32.94 0.67 0.59 0.4 0.37 0.23 Neg 323 - 
3 Female 73 29.6 0.48 0.28 0.37 0.57 0.39 Neg 87 neg 
4 Female 70 46.05 0.51 0.29 0.37 0.47 1.06 Neg - neg 
5 Female  45 29.11 0.59 0.34 0.32 0.36 0.17 Pos 1010 - 
6 Male 31 38.85 0.38 0.31 0.32 0.51 0.33 Neg 223 neg 
7 Female 40 56.01 0.73 0.58 0.46 0.39 0.42 Neg 137 neg 
8 Female 46 34.08 0.35 0.34 0.34 0.94 0.62 Neg 1187 neg 
9 Male 43 24.4 0.35 0.27 0.32 0.85 0.62 Neg 214 neg 
“Non-responders” 
average 
53.4 35.7     Av. change in 
eosin. 0.12 
   
“Responders” 
average 
41.8 28.1     Av. change in 
eosin. 0.41 
   
Comparison Diff 11.7  
p =0.024 
Diff 7.6 
p= 0.005 
    Diff -0.29  
p = 0.17 
   
*Missing values are indicated by – 
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Analysis shows them to be significantly older (difference 11.7 years, 95% C.I. 1.6-
21.8, p=0.024), and heavier (BMI difference 7.6, 95% C.I. 2.4 -12.9, p= 0.005) than 
those who responded to treatment, with a smaller fall in eosinophil count after 
treatment, which did not reach statistical significance (difference -0.29, 95% CI -0.71- 
0.13, p= 0.167).  Four of the seven subjects tested had IgE levels in the normal range.  
5.2.10 Comparison of outcomes for low titre and high titre cases. 
Table 5.4 shows a comparison of the outcomes for the low titre (initial serology ≥ 
0.30 and< 0.40) and high titre (initial serology ≥ 0.40) groups. 
As can be seen, the difference between the two groups in terms of treatment success is 
not statistically significant, and they are very similar in terms of average ELISA titre 
at 3-year follow up. There is a significant difference when compared in terms of 
“treatment effect”, but this not significant when adjusted for initial ELISA titre. 
Table 5.4 Outcome for “low titre” subjects. 
 “Treatment 
success” 
(% success) 
“Treatment 
response” 
(% effective) 
Post treatment 
average ELISA 
(95% C.I.) 
“Low titre” ELISA 
(N=16) 
13 (81.2) 10 (62.5) 0.146 (0.08-0.21) 
“High titre” ELISA 
(N=58) 
52 (89.7) 54 (93.1) 0.143 (0.11-0.17) 
Analysis O.R. 2.0 (95% C.I 
0.44-9.08, p= 0.369 
O.R. 8.1 (C.I. 1.9-
34.0, p= 0.004) 
Adjusted O.R.* 
2.98(C.I. 0.46-19.31, 
p= 0.25) 
Difference=0.003 
(C.I. -0.07-0.06, p= 
0.92) 
Adjusted for initial ELISA titre 
 
5.2.11 Discussion 
The results of this study suggest that control 102 of Strongyloides stercoralis infection 
in this adult Aboriginal population could be achieved by case finding and treatment 
alone. A marked and sustained reduction in infection rates was seen in the study 
group without the need for environmental manipulation, or repeated follow up and 
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treatment beyond the current best practice recommendations.  The advantage with this 
strategy is that it requires no change in the current diagnostic or treatment guidelines, 
simply a sustained clinical response from those agencies providing health care in 
these communities. 
The conditions present in Aboriginal communities differ in several ways from those 
in populations elsewhere in the world, where different strategies for control of  
S. stercoralis have been employed, and therefore the findings in this study may not be 
easily generalized. 
Rates of S. stercoralis infection, as with other soil-transmitted helminths, are thought 
to rise throughout childhood, peaking in late adolescence or early adulthood, and 
remaining relatively constant through adult life [14]. In the study community it is 
likely that most infections occur in childhood and adolescence as a result of 
recreational activities around watercourses. 
A study conducted in Cambodia employed a strategy that involved both case finding 
and treatment and attempts to improve sanitation, and reported success in control of 
infection over a two year follow up 98. The incident rate of new infection was higher 
in this setting when compared to our study, and transmission was facilitated by 
agricultural practices that are not a factor in Aboriginal communities. Furthermore, 
the standard of housing and hygiene facilities in the Cambodian communities was 
lower and more variable.  
It is not the case that improvements in hygiene were not necessary for control of STH 
infections in Aboriginal communities, rather that most of the necessary changes may 
have already occurred over the past few decades. Studies of the prevalence of 
hookworm infection in northern Australia suggest that control has been achieved 
through both pharmacological means and improvements in housing 39, 40. Current 
living conditions in Aboriginal communities remain poor by broader standards, but in 
the current study community all individuals are, at a minimum, housed in purpose 
built dwellings with toilet facilities. 
Mass administration of ivermectin has been advocated for control of S. stercoralis in 
high prevalence communities. This strategy appears to have been effective in Central 
American studies examining the administration of ivermectin for control of 
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onchocerciasis, with sustained falls in the prevalence of S. stercoralis infection in 
areas subject to regular MDA compared to those who are not 99.  
Such MDA programs would potentially have secondary health benefits in Aboriginal 
communities in terms of a reduction in Sarcoptes scabiei infections, with a 
subsequent reduction in Group A streptococcal infection and its sequelae of rheumatic 
fever and post-streptococcal glomerulonephritis. Trials of this approach have been 
conducted in Northern Australia with variable results 12. The results of two MDA’s of 
ivermectin for the treatment of strongyloides in an Australian Aboriginal community 
have recently been published in this journal. A marked reduction in the prevalence of 
strongyloides at 6 and 18 months was demonstrated using this approach 96. Such a 
strategy however, would require the active participation of affected communities and 
public health authorities alike, and agreement on the need for such a program has not 
yet been reached 32. 
5.2.11.1 Clinical effects of treatment 
The principal aim of this study was to determine the effectiveness of a “case finding 
and treatment” approach to controlling S. stercoralis infection in an Aboriginal 
community. No attempt was made in our study to characterize the initial symptoms of 
subjects with chronic strongyloidiasis, and therefore there are no data with regard to 
improvements in the well-being or health of the community in response to treatment. 
A recent, much larger trial published in this journal did examine the benefits in terms 
of symptom control of MDA for strongyloides, and found no evidence of a significant 
change in symptom profile 96. Most discussion of the benefits of controlling 
strongyloides infection has centred on the prevention of hyperinfection in 
immunocompromised individuals, and such patients are routinely treated on a purely 
empirical basis in parts of northern Australia 96. No cases of hyperinfection were 
recorded in the study community during the course of the study. 
Our prior study identified T2DM as a risk factor for failure for treatment of  
S. stercoralis 95. No meaningful association of T2DM with treatment outcome could 
be identified at 3 years because of the very low number (9 subjects, 3 of whom had 
T2DM) failing to seroconvert. Extensive data however have been recorded in regard 
to the metabolic outcome for the subjects in this study and these will be reported on 
separately100. In summary, the data showed a differential effect of treatment for 
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S. stercoralis on the metabolic outcomes for patients depending on their diabetic 
status. The incidence of worsening glucose metabolism in non-diabetic patients (new 
cases of T2DM or glucose intolerance) was higher in the treatment group (RR 3.75, 
CI 1.06-13.2, p=0.04). At the same time improving diabetic control as measured by 
HbA1c was noted in the treated diabetic group (Diff=-1.03, p=0.009). While the low 
numbers in this trial mean that this result should be interpreted cautiously, they are in 
agreement with another recently published study into the effect of albendazole 
treatment for STH infection on subsequent insulin resistance 103. The possible adverse 
effect of treatment on glucose metabolism is of importance when considering the case 
for MDA in strongyloides. As a public health measure, MDA does not allow for 
consideration of the individual clinical state of the subjects being treated, and 
therefore intervention to monitor and improve the glucose metabolism of individuals 
at risk of developing T2DM is not possible.  
Limitations of the present study include its reliance on serological means alone for 
diagnosing S. stercoralis infection, as direct parasitological tests are required to 
ensure maximum specificity. However, as already noted, direct methods lack 
sensitivity, are difficult to employ in remote locations, and can over-estimate the 
response to treatment 26. 
Several caveats need to be raised on the effectiveness and feasibility of a case finding 
and treatment strategy. Firstly, the current study deals only with an adult population, 
and little or nothing is known of the situation with respect to the prevalence of 
infection, and effectiveness of treatment in the paediatric population. Logically it 
would seem likely that infection and re-infection rates might be higher in children, 
where hygiene practices may be less rigorous and activities where infection could 
occur more commonly. Disagreement on the need for elimination in adults still exists, 
and this may be even more so in the case of children. Few clear severe adverse health 
effects of chronic infection have been demonstrated in children, and the major health 
consequence in adults- the occurrence of strongyloides hyperinfection syndrome in 
immunosuppressed patients-has been reported only rarely in children 22, 104. It may 
therefore be reasonable to employ a regimen where cohorts of children are screened 
and treated as part of health screening procedures as they reach adulthood.  
Furthermore, as noted above, there is increasing evidence that pre-existing helminth 
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infections may have beneficial effects on metabolic parameters in later life, and this 
potential effect may need to be taken into consideration when considering treatment 
in populations where type 2 diabetes mellitus is extremely prevalent 105. 
Case finding and treatment also relies on the accurate and sensitive diagnosis of 
infection by the means currently available, as large numbers of false negative tests 
would be a problem for effective control. The similarity in response to treatment 
between the “low” and “high “titre groups in this study suggests that it may be 
appropriate to treat individuals whose ELISA values fall just below the positive range 
when working in a high prevalence community. Further research into the appropriate 
ELISA normal range for these populations may be of benefit. 
Accurate follow up of treated cases would also be important in a case finding and 
treatment strategy. A significant number (9 cases, 9.8%) in this study remained 
ELISA positive throughout the study period despite adequate treatment, and it is 
important to know whether these represent true infections. Repeated re-infection of 
these subjects would seem unlikely as an explanation given the low overall incident 
rate of infection in the population. Resistance of the worm to treatment is certainly a 
possibility, although this is yet to be reported in a human population 18. Alternately, it 
is possible that a persistent antibody response has developed in these individuals in 
the absence of ongoing infection, in a situation analogous to the “serofast” response 
sometimes seen in treponemal infection 106. Further investigation of the 9 subjects in 
this study has not served to settle the matter. Faecal PCR studies were conducted in 6 
cases and were negative, suggesting an absence of infection, or at least an absence of 
larval shedding at the time of testing. Eosinophilia is known to be an unreliable 
indicator of infection 107, however it is perhaps of note that eosinophilia rates that 
differed prior to treatment in the responding and non-responding subjects were almost 
identical following treatment. HTLV-1 infection is known to pre-dispose to severe 
and persistent strongyloides infection 33, but was present here in only one individual. 
IgE levels are commonly elevated in chronic infection but are reported to be normal 
in some cases, particularly in those co-infected with HTLV-1 and in the elderly 108. 
Only two of the patients in this group had elevated levels of IgE at follow up. On 
balance, the further tests conducted on the 9 non-responder cases in this study do not 
support the presence of on-going infection with S. stercoralis. Clearly further studies 
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to characterize the immune response in subjects such as these would be of interest, as 
it is known that changes in relative levels of inflammatory and anti-inflammatory 
cytokines occur in patients following successful treatment for S. stercoralis infection 
109. 
It should be noted that if the 9 non-responder subjects are excluded from analysis on 
the presumption that they are no longer infected, then the prevalence of S. stercoralis 
in this cohort 3 years after treatment falls to just 1.4%, underlining once again the 
success of this treatment strategy. 
5.2.12 Conclusion 
In conclusion, this study provides evidence that control of chronic S. stercoralis 
infection in an adult Aboriginal population may achieved through a process of case 
finding and treatment, using the current best practice guidelines for treatment. This 
strategy could be employed as an alternative to mass drug administration, and does 
not rest upon the need for environmental manipulation.  
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Chapter 6 Outcomes of Treatment for Strongyloides stercoralis in an 
Endemic Community: Metabolic Consequences 
6.1 Introduction 
The final paper in this thesis documents the follow up of this cohort three years after 
initial testing and treatment for S. stercoralis infection with respect to the metabolic 
outcomes. The initial cross-sectional study of this cohort had demonstrated a strong 
negative association between S. stercoralis infection and T2DM, but as has been 
noted, this could not imply causation. The ideal follow-up study, in scientific terms, 
would therefore presumably be a randomized controlled trial, where some individuals 
were treated for strongyloides infection, and some were left untreated, with the 
metabolic consequences being measured subsequently. Such a study would however, 
fail to meet any ethical criteria. The clinical consequences of S. strongyloides are not 
fully understood, and it is in itself a potentially fatal infection in the context of hyper-
infection. Clearly, leaving patients who are known to be infected untreated would be 
unethical in a setting where treatment is readily available. Despite this, a longitudinal 
study could go some way towards revealing any effect of treatment if the population 
of infected and treated individuals could be compared to a group who were 
uninfected, and therefore untreated. It should be noted a measurable difference in the 
subsequent prevalence of T2DM and insulin resistance would rely upon the effect of 
helminth infection on metabolic outcomes being reversible, and this is by no means 
certain. Indeed, evidence from studies into the relationship between past 
schistosomiasis and T2DM suggest that the effect could be persistent, even for distant 
infections47, 48. 
The follow up of this cohort also enabled the metabolic outcome for those infected 
patients with T2DM to be assessed and compared to uninfected individuals with 
T2DM. Lastly, it enables the follow up of the very small number of patients who 
remained strongyloides ELISA positive throughout the follow period, despite 
treatment. These groups may give further insights into the effect of S. stercoralis on 
glucose metabolism. 
At the time it commenced, this study constituted the only longitudinal study to 
examine the metabolic outcome for subjects treated for helminth infection. The 
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“SUGARSPIN” trial44, which examined the effect of treatment for soil transmitted 
helminths on various metabolic parameters, was underway at the same time and 
ultimately came to publication prior to this paper.  
Three years is currently the longest period of follow up achieved in a study such as 
this. Nevertheless, it remains a relatively brief period of time in the context of the 
development of insulin resistance and T2DM, and the numbers successfully followed 
for 3 years is relatively small. Prior studies suggest that the incidence rate of T2DM in 
northern Australian Aboriginal populations is very high, varying with age from 2.2 
per 1000 person-years for those younger than 25 years to 39.9 per 1000 person-years 
for those 45-54 years62. Based on these figures, we expected only 8-12 new cases of 
T2DM in our cohort over the course of follow up, reducing the likelihood of 
demonstrating a statistically significant association with treatment. Greater numbers 
of infected subjects with pre-existing T2DM were available however, allowing 
meaningful comparisons of treated and untreated subjects with regard to control of 
T2DM over this time period. 
Evidence for a longitudinal effect of treatment for S. stercoralis on T2DM and insulin 
resistance would strengthen the case for a causative relationship between helminth 
infection and metabolic disease, which has to this time been based solely upon cross 
sectional observational studies. This would further strengthen the argument for 
considering metabolic outcomes when planning for the treatment, control and 
elimination of helminth infections in “transitional” societies. 
Acquisition of data for this paper was completed by late 2016, and the results were 
published in 2017. 
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6.1.1 Abstract 
Aim: To determine the effect of treatment for Strongyloides stercoralis infection on 
type 2 diabetes mellitus in an Australian Aboriginal population 
Methods: A three-year cohort study of 259 Aboriginal adults living in northern 
Australia. Subjects were tested for S. stercoralis infection, diabetic status and HbA1C 
at recruitment. 92 subjects were ELISA positive for S stercoralis and 91 were treated 
with two doses of ivermectin 0.2mg/kg. Serological cure was assessed after 6 months 
and those who remained positive were retreated. All subjects then underwent the same 
testing at 3 years follow up.  
Results: Follow up was successful in 80% of subjects. Eight new cases of T2DM 
were recorded, 7 in the treatment group and 1 in the non-treatment group (Unadjusted 
RR 7.71, CI 0.98-60.48 p= 0.052. Adjusted RR 5.45 CI 075-35.92, p=0.093) In 
addition, worsening glycemic control (T2DM or newly diagnosed glucose 
intolerance) was recorded in 13 cases (10 treatment group, 3 non-treatment. Adjusted 
RR 3.74, CI 1.06-13.20, p=0.04,)) There was a significant improvement in glycemic 
control in the patients with pre-existing T2DM when treated for S. stercoralis 
compared to the non-treatment group (Diff. -1.03, p= 0.009). 
Conclusion: This study demonstrated a differential effect of treatment for  
S. stercoralis on glucose metabolism in patients with and without T2DM. It showed a 
significant effect on the development of T2DM and glucose intolerance in those 
without T2DM, while improving glycemic control in subjects with pre-existing 
T2DM. Although numbers in this study are small, it suggests that larger studies may 
be of interest. 
6.1.2 Introduction 
Recent research has drawn attention to the possible association between helminth 
infections and both Type 2 diabetes mellitus (T2DM), and metabolic diseases in 
general, such as insulin resistance, vascular disease and cardiovascular disease. This 
has been placed in the context of the wider relationship of diabetes to infectious 
disease, given the rising tide of metabolic illness in the developing world in the 
setting of persisting high rates of infectious, and in particular, parasitic, diseases3. 
Attention has also been drawn to the possibility that decreasing rates of helminth 
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infection in the developing world might impact upon the emergence of T2DM and 
metabolic diseases in these societies110. 
To date, these studies have mostly been retrospective and observational in design, and 
have demonstrated a protective effect of parasitic infections against metabolic 
syndrome and T2DM. The infections studied have included Lymphatic filariasis 
(LF)46, Strongyloides stercoralis77, Schistosomiasis47, 48, 54 and soil transmitted 
helminthes (STH)49, and have included both past infections (Schistosomiasis) and pre-
existing current infections (Strongyloides, LF and STH). Evidence for an effect on 
other metabolic parameters and cardiovascular disease has to date been variable and 
less constant51, 52, 53. 
Immuno-metabolic mechanisms, rather than nutritional effects alone, have been 
proposed to explain the observed relationships. Helminth infections are known to 
induce anti-inflammatory changes in their hosts through the actions of regulatory T 
cells and anti-inflammatory cytokines such as IL-10 and TGF 111 112, 113There is 
laboratory evidence that helminth infection and subsequent eosinophilic infiltration of 
adipose tissue can result in metabolic changes that increase insulin sensitivity in 
peripheral tissues and reduce the likelihood of T2DM8, 9. 
A randomized controlled trial of albendazole treatment for STH infection and its 
effect on insulin resistance (IR) has recently been reported on in Indonesia44, 103. This 
was a household cluster randomized, placebo-controlled trial involving more than 
1500 participants. It was conducted over the course of 12 months, and assessed the 
effect of administration of albendazole on insulin resistance as measured by HOMA-
IR. The study failed to demonstrate an effect at a community level, however it did 
demonstrate a significant effect on IR in helminth infected individuals receiving 
treatment, with IR increasing in this group.   
The current study reports on the 3-year follow up of a cohort of patients treated for 
Strongyloides stercoralis in an Aboriginal community in northern Australia. The 
initial study reported in 2015 and demonstrated a strong negative association between 
pre-existing (current) strongyloides infection and T2DM77. Subsequent follow up at 6 
months demonstrated that T2DM was a risk factor for treatment failure in this 
group95. 
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The current study examines the rate of development of T2DM and glucose intolerance 
in the cohort treated for strongyloides infection, and compares it to the rate in the 
untreated group. In addition, the effect of treatment for strongyloides on glycemic 
control in patients with T2DM is measured, and the outcome for a small group of 
patients with a persistent immunological response to S. stercoralis is also assessed. 
6.1.3 Materials and methods 
6.1.3.1 Patient cohort 
The current study follows up a cohort that was established in 2012/2013 in the course 
of a cross sectional, observational study into the relationship between Strongyloides 
stercoralis infection and T2DM77. The patient group was derived from adult patients 
attending a clinic in a remote Aboriginal community in the Kimberley region of 
northern Australia. Subjects were recruited in an opportunistic manner from the group 
of adults over the age of 20 years attending the community clinic for routine medical 
treatment, and who consented to being tested and treated for S. stercoralis worm 
infection. A process of community consultation prior to the study ensured that the 
study was well accepted. Patients who did decline testing had this recorded in their 
medical record but had no further data recorded for the study.  
Patients who had been previously treated with ivermectin without testing for  
S. stercoralis were excluded from the initial study. Where patients were deceased 
during the course of the follow up period they were excluded from analysis, and 
efforts were made to determine the cause of death. Subjects who had permanently 
moved away from the study community during the course of the follow up period 
were also excluded. A small number of subjects who were in the original cohort 
refused further follow up and they were also excluded. 
6.1.3.2 Parasitological testing 
Patients were tested for Strongyloides stercoralis infection utilizing a commercial IgG 
ELISA test (DRG laboratory), and had other biometric, metabolic and biochemical 
data recorded at presentation, including BMI, HbA1C and full blood examination. All 
patients with an ELISA titre greater than or equal to 0.30 were treated with two doses 
of ivermectin 0.2mg/kg /dose and the entire cohort was followed up after 6 months to 
determine both the effects of treatment on the infected group, and the incidence of 
new infections in the untreated group. The results of this follow up were reported in 
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2015. Full details of these two study protocols and of the study community have been 
published previously77, 95. The current study follows up the same cohort 
approximately 3 years after initial testing, using the same protocol. During the course 
of follow up it became apparent that a small number of patients had remained ELISA 
positive for S. stercoralis throughout the study, despite often repeated treatment 
(defined as “non-responders”). In order to better characterize this group, additional 
investigations were performed at the conclusion of the study period to determine 
whether the patients remained infected with strongyloides, and the nature of the 
immune response that was occurring (see below). Fecal specimens were taken to test 
for S. stercoralis DNA and other STH infections, using a multivalent PCR test 
developed at Western Diagnostic pathology in Perth, Western Australia.   
6.1.3.3 Metabolic testing 
Diabetes status was determined on the basis of HbA1c, or random blood glucose 
levels (BGL), and/or treatment status, with T2DM defined as an HbA1c of ≥ 6.5%(48 
mmol/mol) or a random BGL of >11.2 mmol/l, or any patient currently receiving 
treatment for T2DM on the basis of past assessments as outlined above. Additionally, 
impaired glucose tolerance (IGT) was defined as any patient with an HbA1c ≥ 
6.0%(42 mmol/mol) but < 6.5%114 in the absence of T2DM therapy. Investigations 
that rely upon a fasted status (fasting BGL or glucose tolerance testing) are rarely 
performed in the clinics where this study was undertaken due to the transient nature of 
the population and their cultural practices, and they were therefore not included as 
part of this study. All testing was performed by an Australian government accredited 
commercial laboratory (Pathwest Laboratory, Perth W.A.) 
For patients taking treatment for T2DM, a treatment adherence measurement tool was 
devised specifically for this study. This involved calculating the number of weekly 
packs of prescribed medicine that the patient collected from the clinic in the 12 weeks 
prior to their final HbA1c measurement, and thereby designating each patient with a 
score between 0 and 12.  
6.1.3.4 Immunological parameters 
Additional blood specimens were taken from the “non-responder” group, to measure 
baseline levels of IL-10, IL-6 and TNF-α, and for whole blood stimulation studies to 
determine the capacity of the patient’s white cells to produce these cytokines.  
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All subjects were clinically well at the time of examination. In particular they showed 
no signs of fever or infection, were not using steroids, and had no known relevant 
medical conditions, other than T2DM or glucose intolerance. Comparison samples 
were also taken from a group of subjects who were initially positive for strongyloides 
infection, remained positive at 6 months follow up, but ultimately returned negative 
samples at 3 years (defined as “responders”).  Specimens were packed in ice and 
transported to James Cook University, Cairns, Queensland where analysis was 
commenced about 96 hours after the blood was drawn. Mononuclear cells were 
isolated using density gradient separation methods according to the manufacturer's 
instructions (Lymphoprep TM), and then stimulated with media or LPS (20ug/ml), 
and analyzed for production capacity of the cytokines TNF-, IL-6 and IL-10 after 
incubation, using a commercial ELISA platform (affymetrix eBioscience).  
6.1.4 Statistical methods 
Descriptive statistics included mean, medians (where data was not normally 
distributed) and percentages, and their respective 95% confidence intervals (CI). 
Comparisons of variables between the treated and untreated groups used independent 
samples t-tests and Mann–Whitney U-tests for continuous variables, and Chi-square 
tests for categorical variables. 95% CI for medians was obtained by bootstrapping. 
The association between treatment history and subsequent diabetes status was 
assessed using a log binomial generalized linear model. An adjusted model was 
performed using age, sex, baseline HbA1c and change in BMI. Finally, the 
calculations were repeated excluding those for whom treatment had been 
unsuccessful. 
A similar process was undertaken comparing treatment history and change in HbA1C 
for patients who were initially in the diabetes group. In this case multivariable linear 
regression was used, and adjustment was also undertaken for initial HbA1C and for 
adherence to prescribed medication.  
Finally, an analysis of the “non–responding” group was performed utilizing 
independent samples t-tests for comparison with the responding group in regard to 
age, sex, eosinophilia, HbA1c and change in HbA1c. Cytokine levels were analyzed 
using mixed effects models. All analyses were undertaken using STATA v13 
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(StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: 
StataCorp LP). 
6.1.5 Regulatory commitments 
The protocol for this study was approved by the Kimberley Aboriginal Health 
Planning Forum. Ethical approval for the study was obtained through the Western 
Australian Aboriginal Health Ethics Committee (HREC Reference 515). 
Further approval for the cytokine studies was sought and obtained in 2016. Patients 
undergoing these tests were counseled, and provided additional written consent. 
6.1.5.1 Funding 
This research did not receive any specific grant from funding agencies in the public, 
commercial, or not-for-profit sector. 
6.1.6 Results 
Follow-up outcomes and baseline demographic and metabolic data are recorded in  
 
Figure 6.1 and Table 6.1. 
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Figure 6.1 Follow-up outcomes at 3 years. 
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Table 6.1 Baseline Demographic and metabolic data by treatment group. 
  Not treated Treated Overall Sig. 
  N % N % N % P 
Age <30 18 10.7 17 18.7 35 13.5 0.141 
 30-39 64 38.1 26 28.6 90 34.8  
 40-49 44 26.2 20 22.0 64 24.7  
 50+ 42 25.0 28 30.8 70 27.0  
 Total 168 100.0 91 100.0 259 100.0  
Sex Male 69 41.1 37 40.7 106 40.9 0.949 
 Female 99 58.9 54 59.3 153 59.1  
 Total 168 100.0 91 100.0 259 100.0  
Glucose 
metabolism 
Normal 54 32.2 40 43.9 94 36.3 <0.001 
 IGT 13 7.7 19 20.9 32 12.4  
 T2DM 101 60.1 32 35.2 133 51.3  
 Total 168 100.0 91 100.0 259 100.0  
Tests  N Mean(SD) N Mean(SD) N Mean(SD)  
BMI  158 29.9 (7.2) 88 29.3 (8.5) 246 29.7 (7.7) 0.543 
HbA1c % 161 7.6 (2.1) 85 7.0 (1.9) 246 7.3 (2.0) 0.041 
 (mmol/mol)  (59.6)  (53)  (56.3)  
Random BGL mmol 162 9.7 (5.4) 89 8.7 (4.8) 251 9.4 (5.2) 0.148 
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Follow up was successful in 207(79.9%) of subjects. Of those lost to follow up, 19 
were from the treatment group and 33 from the untreated group (OR 1.06, CI 0.56- 
1.99, p= 0.86). The largest group lost to follow up was those shifting to other 
communities or in the prison system. Eighteen subjects died during the follow up 
period, comprising 7 from the treatment group and 11 from the untreated group (OR 
1.18, CI 0.44- 3.16, p=0.74). Cause of death, where known, was determined from the 
medical records, and comprised cardiovascular disease (7), malignancy (2), 
respiratory disease (2), sepsis (2), and chronic renal failure (1). 
Of note are the markedly different baseline tests of glucose metabolism between the 
infected (treated) and uninfected (untreated) groups (Chi-squared <0.001). This 
difference in the prevalence of T2DM was the subject of our first paper regarding this 
cohort77. When considering outcomes at 3-year follow up, clearly the proportion in 
each group who began with IGT is of relevance. However, when considering the 
effect of IGT on outcome it is not the raw baseline data that is of relevance, rather the 
proportion in each group with IGT, of those patients without diabetes who completed 
follow-up at 3 years. (From Table 6.2 and Table 6.3, N=207. 18/59 (30.5%) with IGT 
for the treated group and 12/54(22.2%) for the untreated group, Chi-squared=0.984 on 
1 d.f, P=0.321.) Thus, while there is a trend for IGT to be more common in the treated 
group, this does not reach statistical significance. This trend is allowed for in our 
adjusted GLM by introducing a term for baseline HbA1c that reflects initial IGT 
status (see Table 6.4, Table 6.5, and Table 6.6). 
 
Table 6.2 and Table 6.3 show metabolic parameters at baseline and three-year follow 
up according to treatment group. 
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Table 6.2 Comparison of metabolic parameters for subjects without T2DM at baseline and follow up (N=95). NT =not treated T =treated 
          NT group N Mean       . SD T grp N Mean SD Sig.  
BMI Baseline 50 28.50 6.86 42 27.96 8.04 0.731 
 Final  50 29.89 6.79 40 28.77 8.25 0.483 
 Change#  47 0.95 3.78 40 0.63 2.20 0.636  
HbA1c (%) 
(mmol/mol) 
Baseline  48 5.77 (39.6) 0.30 40 5.80 
(39.9) 
0.32 0.738 
 Final  51 5.65 (38.3) 0.31 40 5.72 (39.0) 0.24 0.222 
 Change#  46 -0.12 0.28 38 -0.08 0.22 0.525  
Random BGL 
(mmol/l) 
Baseline  49 5.81 1.48 40 6.33 2.15 0.179 
 Final  46 6.57 1.88 40 7.12 1.84 0.179 
 Change#  44 0.73 21.9 38 0.77 2.94 0.949  
*Based on independent samples t-test 
#Final – Baseline. Missing values excluded 
N=95. Discrepancies in numbers for individual measures are due to missing values 
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Table 6.3 Comparison of metabolic parameters for subjects with T2DM at baseline or follow up (N=112). NT= not treated T =treated 
         NT group N Mean SD     T group N Mean SD Sig.  
BMI Baseline  77 30.85 6.72 31 30.46 7.23 0.789 
 Final  78 30.14 6.43 32 30.67 7.50 0.709 
 Change#  76 -0.75 2.70 31 0.15 2.85 0.125 
HbA1c (%) 
(mmol/mol) 
Baseline 80 8.39 (68.2) 1.78 31 8.55 (69.9) 2.21 0.697 
 Final  80 8.84 (73.1) 2.31 32 8.25 (66.7) 2.14 0.214 
 Change#  80 0.45 1.58 31 -0.32 1.88 0.032 
Random BGL 
(mmol/l) 
Baseline  79 12.07 5.79 32 11.42 5.44 0.585 
 Final  80 13.56 6.29 30 13.10 6.21 0.733 
 Change#  70 1.57 6.60 30 1.63 7.23 0.971 
*Based on independent samples t-test 
#Final – Baseline. Missing values excluded 
N=112. Discrepancies in numbers for individual measures are due to missing values 
 
 96 
Table 6.2 and Table 6.3 show the metabolic parameters for the patients with and 
without diabetes by treatment group at recruitment and after three years. There are no 
significant differences between treated and untreated subjects in the baseline groups 
apart from a significant difference in the change in HbA1c between the treated and 
untreated diabetic groups, that is discussed in more detail below. 
In particular it should be noted that there is no significant difference in BMI between 
the treated and untreated groups, either at baseline or follow up, and that the change in 
BMI is also statistically similar between these two groups. 
6.1.6.1 Follow up of patients without T2DM 
 
Table 6.4 shows the outcome three years after treatment for patients who were 
initially classified “no diabetes” (normal and IGT), and demonstrates an increased 
risk of developing diabetes in the treated group. 
Table 6.4 Newly developed diabetes at three-year follow-up. 
Treatment status 
No diabetes (%) 
(normal & IGT) Diabetes* (%) Total 
Untreated 53 (98.2) 1 (1.8) 54 
Treated 42(85.7) 7(14.3) 49 
Total 95 8 103 
 Chi2= 5.54  P= 0.019  
Unadjusted log binomial 
GLM 
 
RR =7.71 
 
95% CI 0.98-60.48 
 
P =0.052 
Adjusted log binomial 
GLM** 
 
RR= 5.45 
 
95% CI 0.75-39.52 
 
P= 0.093 
GLM: generalized linear model RR: Rate ratio 
* Those with HbA1C≥ 6.5% at 3-year follow-up. Three of the new cases in the Treated group 
developed from subjects with normal baseline HbA1c. The remainder had IGT. 
** Adjusted for age, sex, baseline HbA1c and change in BMI 
 
 
This trend is also present in the group moving from normal HbA1c to impaired 
glucose tolerance (Table 6.5), although this does not achieve statistical significance.  
  
 97 
 
Table 6.5 Newly developed glucose intolerance at three-year follow up. 
Treatment status Normal (%) IGT* (%) Total 
Untreated 40 (95.2) 2 (4.8) 42 
Treated 25 (89.3) 3 (10.7) 28 
Total 65 5 70 
 Chi2= 0.89  P= 0.34  
Unadjusted log 
binomial GLM 
 
RR =2.25 
 
95% CI 0.40-12.62 
 
P =0.36 
Adjusted log 
binomial GLM** 
 
RR= 2.47 
 
95% CI 0.52-11.64 
 
P= 0.25 
GLM: generalized linear model RR: Rate ratio 
N=70. Three patients in the treated group who were “normal” at baseline developed T2DM at 3 years 
* Impaired glucose tolerance. Those with HbA1c≥ 6.0 but< 6.5 at 3-year follow up 
** Adjusted for age, sex, baseline HbA1c and change in BMI 
 
When the two groups are combined, the trend for worsening glucose metabolism in 
the treated group is once again evident (Table 6.6). 
 
Table 6.6 Worsening glucose metabolism at three-year follow up. 
 
Treatment status No worsening (%) Worsening* (%) Total 
Untreated 51 (94.4) 3 (5.6) 55 
Treated 39 (79.6) 10 (20.4) 49 
Total 90 13 103 
 Chi2= 5.14  P= 0.023  
Unadjusted log 
binomial GLM 
 
RR =3.67 
 
95% CI 1.07-12.58 
 
P =0.038 
Adjusted robust 
poisson regression** 
 
RR= 3.74 
 
95% CI 1.06-13.20 
 
P= 0.040 
 
RR: Rate ratio 
* Those with HbA1c≥ 6.5%, or newly diagnosed glucose intolerance at 3-year follow up 
** Adjusted for age, sex, baseline HbA1c and change in BMI 
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6.1.6.2 Follow up of patients with T2DM 
Table 6.7 demonstrates the outcome in terms of HbA1c for the patients who had 
T2DM at the initial assessment.  
Table 6.7 Effect of treatment on HbA1c in patients with diabetes over 3 years. 
Group Number Mean change in HbA1c 
% 
Coefficient of change 
score  
 
Untreated 79   0.43 (C.I.  0.08- 0.79)   
Treated 25 -0.60 (C.I. -1.41- 0.22)   
Linear regression   -1.03 (C.I. -1.80- -0.26) P=0.009 
Adjusted for 
baseline* 
  -0.94 (C.I. -1.71- -0.16) P=0.019 
Adjusted linear 
regression** 
  -1.00 (C.I. -1.84- -0.15) P=0.021 
* Adjustment was made for initial HbA1C on the basis that a fall in HbA1C would be more likely from 
a high starting point 
** Adjusted for age, sex, change in BMI, initial HbA1C and adherence to prescribed medication. 
 
A clear improvement in HbA1c over three years is demonstrated for those who were 
treated for a positive strongyloides ELISA. This improvement persists when corrected 
for initial HbA1c, change in BMI and compliance with prescribed treatment. 
 
6.1.7 Follow up of “non-responders” 
Table 6.8 shows demographic and treatment outcome data for the small group (9 
patients) who failed to respond serologically to treatment, and remained ELISA 
positive after 3 years, despite repeated treatment. Where appropriate, comparisons 
with the remainder of the treated group who responded to treatment (N=82) are 
included. The non-responder group was older (difference 11.7 years, CI 1.5-21.8, 
p=0.01)), and heavier (BMI difference 7.6, CI 2.4-12.9, p= 0.002) than the group who 
responded to treatment, and tended to have a lower initial Strongyloides ELISA and 
lower eosinophil count, although these results did not achieve statistical significance. 
Most notably, this group demonstrated a marked improvement in glycemic control, as 
measured by HbA1c, when compared to the group who responded to treatment 
(Change in HbA1c difference 1.20, CI 0.34-2.06, p=0.007)).
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Table 6.8 Treatment after 3 years. “Non-responders” compared to “Responders”. 
 Age 
Initial 
ELISA 
Initial HbA1C 
% (mmol/mol) Initial BMI 
Final 
ELISA 
Final HbA1C 
% (mmol/mol) 
Final 
BMI 
Change in 
HbA1C% 
1 Male * 75 0.65 10.6 (88) 30.37 0.45 6.4 (46) 30.1 -2.2 
2 Female 58 0.67 6.1 (43) 32.94 0.4 6.1 (43) 34.9 0 
3 Female 73 0.48 6.3 (45) 29.6 0.37 5.9 (41) 31 -0.4 
4 Female 70 0.51 6.1 (43) 46.05 0.37 5.9 (41) 46.2 -0.2 
5 Female * 45 0.59 9.8 (84) 29.11 0.32 6.1 (43) 28 -3.7 
6 Male 31 0.38 6.1 (43) 38.85 0.32 6.1 (43) 34 0 
7 Female 40 0.73 6.1 (43) 56.01 0.46 5.9 (41) 55 -0.2 
8 Female 46 0.35 12.8 (116) 34.08 0.34 10.5 (91) 34.4 -2.3 
9 Male 43 0.35 5.6 (38) 24.4 0.32 5.5 (37) 24.6 -0.1 
Average 53.4  7.7 (61) 35.7  6.5 (48) 35.4 -1.23 
Responders 41.8  6.9 (52) 28.1  6.9 (52) 28.8 -0.03 
Comparison Diff 
11.7  
p=0.024 
 Diff 0.83 % 
p= 0.25 
Diff 7.6 
p= 0.005 
 Diff -0.40 % 
p= 0.55 
 -1.20 % 
p= 0.007 
*These patients required cessation of treatment for T2DM during the course of follow up due to persistently low blood glucose levels 
*** Fecal PCR testing was performed on 6 of the 9 subjects and was negative in all cases 
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Figure 6.2 Cytokine production by response to treatment for Strongyloides stercoralis. 
This figure charts the cytokine production values obtained for six of the “non-
responder” patients in comparison to a group who responded to treatment. There are 
differences between the “non-responders” and “responders” when it comes to levels 
of TNF– and IL-10 produced on stimulation with LPS, with the group that shows a 
persistent antibody response to S. stercoralis having lower levels of cytokine 
production on crude analysis. 
6.1.8 Discussion 
The results of this study and their statistical significance clearly needs to be 
interpreted in the light of the small numbers involved and the differing baseline 
metabolic measures of the groups compared. As noted above, pre-existing IGT tends 
to be commoner in the treatment group, although this does not reach statistical 
significance. Having said this, the current study gives support to the hypothesis that 
pre-existing infection with the helminth Strongyloides stercoralis can have a 
beneficial effect on glucose metabolism in humans. When taken together the study 
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findings demonstrate a differential effect of treatment for S. stercoralis infection on 
metabolic outcomes dependent on the diabetes status of the subjects. The results of 
our study also support the recent findings by Tahapary et al who found that treatment 
of STH infected individuals with albendazole was associated with an increase in 
insulin resistance after 12 months.103  
The current study is the longest duration of follow-up to demonstrate an association 
between treatment for helminth infection and worsening glucose metabolism and it 
does so in three ways. 
Firstly, follow up of subjects without diabetes at the commencement of the study 
showed that those who were treated for strongyloides infection had an unadjusted 7.7 
times greater chance of being diagnosed with T2DM in the 3 years following 
treatment than an uninfected and untreated group. This relationship persisted when 
adjusted for age, sex and change in BMI and initial HbA1c, although the strength of 
the relationship was reduced (RR 5.85 C.I. 0.75-39.52, p= 0.093) and it failed to 
achieve statistical significance. Furthermore, patients without T2DM had a tendency 
to develop impaired glucose tolerance at a higher rate than the untreated group. When 
both these groups are considered together- that is to say as “worsening glucose 
metabolism”, the relationship persists and is stronger (Adjusted RR 3.74, C.I. 1.06-
13.20, p= 0.04) 
A cogent theory to explain this observation can be developed from what is already 
known about the effect of helminth infections on insulin sensitivity. Wu et al (2010)8 
demonstrated that eosinophilic infiltration of adipose tissue was capable of inducing 
the production of alternatively activated macrophages which then enhanced insulin 
sensitivity in peripheral tissues via means of the production of anti-inflammatory 
cytokines such as IL-10 and TGF-, and the concomitant down-regulation of pro-
inflammatory cytokines. It is feasible therefore, that removing or reducing this effect 
through treatment of a pre-existing strongyloides infection, could worsen insulin 
sensitivity in a susceptible individual and result in worsening glucose metabolism.
This study also examined the outcome in terms of HbA1c control for patients with 
T2DM who were treated for strongyloides infection, in comparison to the cohort who 
were untreated. A strong treatment benefit was demonstrated with an average 
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difference in HbA1c of -1.03 in the treated group. This benefit persisted when 
corrected for age, sex and change in BMI. It also persisted when allowance was made 
for adherence to prescribed medicines. The effect was ameliorated when adjusted for 
initial HbA1c, on the presumption that it is easier to achieve a large fall in HbA1c if 
beginning from a high value.  
There are several possible explanations for this observation. Firstly, the beneficial 
effect of pre-existing strongyloides infection may be persistent despite treatment of 
the infection, resulting in an improvement in glycemic control over 3 years. This 
would seem to be in keeping with some of the existing observational studies of the 
relationship between infections such as schistosomiasis and T2DM, as these studies 
demonstrated an effect purely on the basis of past, rather than ongoing, infections47, 48, 
54. It is also feasible that strongyloides infection in patients with existing T2DM 
resulted in worsening of diabetes control, and that treatment subsequently improved 
the situation. The infected diabetic group had higher HbA1c on average at the outset 
and there was a higher eosinophil count in infected patients with T2DM107. It is 
plausible that the group with diabetes therefore had a more pronounced Th2 weighted 
immune reaction with higher levels of Th2 inflammatory cytokines, rather than a 
modified Th2 response with high levels of the anti-inflammatory cytokines IL-10 and 
TGF- as discussed above. Treatment of the infection could therefore have reduced 
the intensity of the inflammatory reaction and resulted in improved glycemic control. 
A recent study by de Ruiter et al has demonstrated a differential effect of treatment 
for STH infection on measures of the TH2 weighted immune response, reporting a 
reduction in levels of Ig E, but a tendency to increased levels of IL-5 in patients 
treated with albendazole. They conclude that treatment for helminth infection may 
have differential effects on TH2 mediated responses, that need to be taken into 
account when considering the impact of “de-worming” treatment on non-
communicable diseases.115 
Lastly, support is given to the hypothesis by examining the small group of patients 
who failed to respond to ivermectin treatment and remained ELISA positive to  
S. stercoralis throughout the course of the study. Results of fecal testing suggest that 
these patients no longer had an active S. stercoralis infection. Whether the persistence 
of antibodies in this group represents true treatment failure, or whether it simply 
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reflects ongoing antibody production in the absence actual infection, it does suggest 
that at least some of the immunological changes caused by strongyloides infection 
persisted in this group of patients for the duration of the study. 
Examining the characteristics of this group, they are on average older and heavier, yet 
despite this they showed a marked improvement in HbA1c over the course of the 
study in comparison to the successfully treated group. Examining them case-by-case, 
all had stable or falling HbA1c over the study period, and of the three subjects 
withT2DM, two had their HbA1c fall into the “non-diabetic” range despite having 
their diabetes medication ceased during this period.  
The cytokine studies performed on this group involve only a very limited number of 
subjects, and were intended therefore as a hypothesis generating exercise. Past studies 
have characterized the changes in serum cytokine levels that occur after the treatment 
of otherwise well individuals109. Our study emulates that performed by Wiria et al49 
which failed to find any change in cytokine levels following treatment for STH 
infection. Despite its limited scope, our study demonstrates a significant difference 
between community members with successfully treated past infection and those with 
persisting positive ELISA to S. stercoralis, and suggests that persisting ELISA 
positivity to S. stercoralis may have some effect in reducing cytokine production. 
Adequately powered studies comparing infected individuals, treated individuals and 
suitable controls may therefore be of benefit. 
This study has several limitations. Firstly, the numbers involved are very small; only 
8 new cases of T2DM were diagnosed during the course of the study, and the follow 
up period of three years is relatively short in the context of a chronic metabolic 
disease like T2DM. Further, the tests used to diagnose T2DM and glucose intolerance 
are purely clinical ones and therefore relatively insensitive for assessing glucose 
metabolism. Five of the eight new cases of T2DM had an HbA1c in the range of 
6.0%- 6.5% at the commencement of the study, meaning that relatively small changes 
in HbA1c resulted in a new diagnosis. 
Due to logistical and ethical limitations, when performing the cytokine measurements 
in this study we were unable to test untreated patients and were not able to obtain 
control specimens from uninfected subjects in the study community. 
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Lastly, the status of patients involved in the study, with regard to infection and 
treatment, was necessarily not blinded to either the investigators or the subjects, 
introducing the possibility of treatment bias. This was mitigated somewhat by the fact 
that the ongoing care of patients in this clinic was a collaborative effort between 
several clinicians, and the existence and nature of the study being performed was not 
disclosed to those involved in the day to day management of T2DM. 
Despite these shortcomings, a statistically relevant relationship has been demonstrated 
between treatment for S. stercoralis infection and subsequent glucose metabolism, 
suggesting that further studies with larger numbers of patients and a longer time frame 
may be of interest. 
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Chapter 7 Strongyloides stercoralis and T2DM: 
Conclusions and New Directions 
The five papers that constitute this thesis present findings that can be divided broadly 
into two categories. Firstly, there are findings which speak directly to the hypothesis 
that helminth infection, in this case with Strongyloides stercoralis, has an impact on 
the development and treatment of type 2 diabetes mellitus. Secondly, the papers 
provide insights which impact on the diagnosis, treatment and control of 
Strongyloides stercoralis infection, particularly in the Australian context. In this 
conclusion, I wish to consider both of these areas separately but pay particular 
concern to the situations where the two elements impact upon each other. I will then 
consider what practical impact the results might have on research in both the field of 
T2DM control and treatment, and the control of Strongyloides stercoralis infection in 
the Australian context. 
7.1 Conclusions: Metabolic Outcomes 
The results delivered in this thesis support the hypothesis that chronic helminth 
infection can impact upon glucose metabolism in human beings, and that an immuno-
metabolic explanation for this finding is most plausible. They do so in the following 
ways. 
Firstly, the initial cross sectional observational study demonstrates a strong negative 
association between pre-existing S. stercoralis infection and a diagnosis of T2DM in 
an Aboriginal population. Crucially this association persists even after correction for 
factors such as age, sex and BMI, which suggests that a purely nutritional explanation 
for the findings may not be valid.  Whilst in a study of this kind causation can clearly 
not be implied, the question of a plausible mechanism for the relationship falls 
heavily in favour of the infection resulting in a lower prevalence of T2DM, rather 
than the converse.  
In order to conclude instead that T2DM results in a lower prevalence of strongyloides 
infection, we would need evidence of a plausible mechanism. Candidates for such a 
mechanism would include the prospect that hyperglycaemia can protect against the 
establishment of chronic helminth infection, that T2DM patients receive preferential 
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treatment for strongyloides infection or that this treatment is more effective, or that 
patients with T2DM and impaired glucose metabolism behave in a way which 
protects against the acquisition of worm infection. In none of these cases is there any 
evidence to support these hypotheses, and in the case of treatment effectiveness, there 
is evidence to the contrary95. On the other hand, laboratory evidence into the effects 
of experimental worm infections on metabolism has provided direct evidence that 
helminth infection can protect against T2DM, and has provided a plausible immuno-
metabolic pathway for such an effect8, 9. 
Secondly, this thesis provides evidence that T2DM impacts upon the short-term 
success of treatment for S. stercoralis infection. Again, several theories could explain 
this observation, including reduced absorption of ivermectin in diabetic patients, drug 
interactions with medications commonly prescribed for T2DM, and the possibility 
that patients with T2DM have a higher proportion of recent infections, and therefore a 
higher worm burden, with a correspondingly higher rate of treatment failure. Once 
again, evidence to support any of these hypotheses is lacking. An immune-metabolic 
explanation can once again be developed, as the inflammatory environment in 
patients with T2DM is known to differ greatly from those with normal glucose 
metabolism, suggesting that worm killing and clearance could therefore be affected. 
Little in the way of experimental evidence exists to support this theory, although one 
paper has pointed to a role for raised levels of the adipokine resistin and reduced 
worm clearance in helminth infections56. 
Lastly, the follow up of this cohort three years after treatment provides evidence that 
treatment for S. stercoralis infection may result in worsening of glucose metabolism 
when compared to an untreated and uninfected cohort. This is evident in the increased 
prevalence of “worsening glucose metabolism” in previously non-diabetic subjects, 
and is further supported by the limited cytokine studies, and follow up of “non-
responding” patients.  
This is one of only two studies to examine prospectively the metabolic outcomes of 
treatment for helminth infection103, and although the numbers are small and the follow 
up period relatively brief, the results suggest that an effect is present, and that larger 
and more extensive studies may be of interest. Significantly, the results also suggest 
that the successful treatment of S. stercoralis infection may have a beneficial effect on 
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glycaemic control in patients with pre-existing T2DM. This is not at odds with the 
other findings of the study, rather it emphasizes the very different immunological and 
inflammatory conditions which pertain in diabetic patients when compared to non-
diabetics, and the relationship that this has to the immunological reaction to helminth 
infection. Our results are consistent with a more prolonged and intense inflammatory 
reaction in patients with T2DM and S. stercoralis infection, when compared to non-
diabetics, and it is therefore conceivable that treating the infection in diabetics may 
reduce the inflammation, and thus improve diabetic control. 
The possibility that treatment for Strongyloides stercoralis, or indeed any helminth 
infection, might worsen the impact of T2DM on either an individual or public health 
level, is clearly of great concern. The emergence of T2DM and metabolic illness in 
regions where helminth infection is common has generally been attributed to the 
dietary and lifestyle changes which are an inevitable consequence of development. 
The prospect of a reduction in the prevalence of helminth infection in itself also 
contributing to this problem now also needs to be taken into consideration. 
The situation in the Aboriginal communities of northern Australia is at the extreme 
end of this problem, with T2DM present at epidemic levels, resulting in enormous 
morbidity and mortality, and affecting progressively younger cohorts of patients4. The 
prospect of worsening this situation through the treatment of strongyloides, which in 
itself has an uncertain disease impact at a population level, is clearly a concern. A 
more pertinent question however, might be not to ask why the presence of pre-
existing helminth infection prevents T2DM in some individuals, but to ask why 
T2DM and insulin resistance is occurring in such large numbers in these populations 
of relatively young people. If we accept the hypothesis that long term 
immunomodulation by helminths producing a persistent modified Th2 immune 
response can protect against T2DM, then it would seem reasonable to hypothesise that 
a persistent Th1 weight immune activation in response to bacterial and viral infection 
may pre-dispose to the development of metabolic illness in the same group9. Despite 
advances in public health and housing, Aboriginal children and young adults living in 
remote communities grow up and live in a sea of chronic and acute bacterial and viral 
infection, suffering from conditions such as chronic suppurative ear disease, 
streptococcal skin infection, pneumonia, dental sepsis, gingivitis, and venereal 
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diseases in extremely high numbers. For many therefore, the years from birth to 
maturity are characterized by an almost constant activation of their Th1 weighted 
immune response, with possible consequent effects on their glucose metabolism. 
In addition to the possible direct effects of persistent infection on metabolic outcomes, 
the effects of treatment for these conditions also needs to be considered. The frequent 
and widespread use of broad spectrum antibiotics for actual and presumed infection is 
almost certainly having an effect on the intestinal flora and “gut microbiota” of 
Aboriginal children. Alterations in the gut microbiota are known to be associated with 
T2DM and insulin resistance41. Prompt medical treatment for common infections with 
a range of antibiotic agents is now universally available in Aboriginal communities, 
but the decision to treat is frequently delivered through protocols administered by 
nursing staff, whose approach is understandably influenced by the high prevalence of 
disease, and the consequences of non-treatment of conditions such as otitis media and 
streptococcal infection on future morbidity and mortality. While clearly a reduction in 
the frequency of these infections is of primary importance, measures which can 
improve the precision of diagnosis and effectiveness of treatment, and thereby reduce 
the unnecessary administration of antibiotics could also be of benefit. 
Recognition of the role of chronic inflammation in the pathogenesis of T2DM, and 
the capabilities of helminths to reduce inflammation, raises the possibility that novel 
agents for the treatment and prevention of T2DM may be developed through further 
research in this field 
In recent years there has been increased interest in the role of anti-inflammatory 
agents in the treatment of T2DM and its complications, and clinical trials using 
inhibitors of cytokines such as TNF- and IL-1B, and less specific anti-inflammatory 
agent such as salicase, have been conducted with varying results74, 116. 
Helminths are known to produce their immunological effects through the production 
of excretory-secretory proteins which have potent effects on the host immune system 
and the nature and effects of a number of these substances have been documented75, 
117. Furthermore, it has been established that low level clinical exposure to some 
helminth infections such as T. suis and hookworm is safe. A number of clinical trials 
have been conducted into the effect of exposure to worm infections and to the 
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excretory-secretory proteins helminth infections produce, on inflammatory and atopic 
illness such as inflammatory bowel disease, asthma and atopic eczema118. To date 
there have been no studies employing this approach with metabolic disease.  
7.2 Conclusions: Control of S. stercoralis Infection 
Aside from its findings on the metabolic effects of helminth infection, this thesis also 
provides insights into the epidemiology, diagnosis and management of S. stercoralis 
infection in Australia. A clear picture of the extent and prevalence of strongyloides 
infection in Australia is still lacking, and the data in this thesis add to the picture 
being developed by current projects to improve the extent and quality of 
information12. 
Results of treatment follow up after 6 months demonstrate that ivermectin is an 
effective treatment for strongyloides infection in this community, and are compatible 
with results achieved elsewhere in the world, reinforcing the role of ivermectin as the 
treatment of choice for this condition. 
In the field of diagnostics, this thesis provides further evidence that IgG ELISA 
testing is valid for the diagnosis and follow up of strongyloides infection. 
Furthermore, it provides evidence that the use of a lower cut-off point for ELISA 
testing in high prevalence communities may be valid, and that more extensive studies 
in this area may be of use. 
The data with regard to eosinophilia and strongyloides infection demonstrates that 
eosinophilia is not a reliable proxy test for strongyloides infection in high prevalence 
settings, and where other causes of eosinophilia are also prevalent. The presence of 
higher and more constant rates of eosinophilia in T2DM patients when compared to 
those without diabetes, once again demonstrates evidence of a differential immune 
reaction. The higher rate of eosinophilia found in diabetic patients suggests a more 
robust Th2 weighted immune reaction and a relative absence of immunomodulation in 
these cases, giving further support to the immuno-metabolic model. 
Lastly, the three-year follow up data demonstrates that a “case finding and treatment” 
model for the diagnosis and treatment of strongyloides has been highly effective in 
reducing the prevalence of infection in adults living in this community. 
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These findings, along with the core finding that S. strongyloides infection has an 
effect on the prevalence and outcome of T2DM, has clear implications for strategies 
being considered for the control and elimination of this infection in Australia and 
internationally. Broadly speaking, the current strategies available include mass drug 
administration in endemic communities, environmental manipulations to reduce 
exposure to the worms, and the case finding and treatment approach employed in this 
thesis. 
Mass drug administration has been shown to have significant effects on the 
prevalence of infection in regions where it has been employed, both as a consequence 
of programs to eliminate onchocerciasis in Central America99, in association with 
environmental measures in Cambodia98, and in dedicated programs conducted in 
Northern Australian Aboriginal communities96. It should be noted that while 
reductions in prevalence have been achieved through MDA, there is as yet no 
evidence that this can lead to interruption of transmission or elimination of the 
infection. 
Environmental manipulations such as improved hygiene have been beneficial in the 
context of treatment programs, and circumstantially would seem to be responsible for 
the long-term control and eradication of the infection in the developed world. Recent 
studies into the possible role of dogs as a reservoir for some human infections raise 
the possibility that this may also be important in control programs17. 
MDA raises difficulties of its own, such as community acceptance, sustainability, and 
most tellingly, the possibility of adverse and unforeseen consequences. Balanced 
against this is the uncertain disease burden produced by chronic S. stercoralis 
infection, but the very real risk of catastrophic hyper-infection that exists, particularly 
in immunocompromised individuals. The possibility, and now the evidence, that 
treatment for strongyloides may produce adverse metabolic consequences is clearly a 
factor to be considered in any MDA program, particularly in communities where 
T2DM and its effects are already responsible for such a heavy disease burden. If 
public health measures such as MDA were to have a negative impact on T2DM on a 
community level, then this could only be countered by other community wide public 
health measures to combat T2DM. In contrast, a case finding and treatment approach 
enables the individual circumstances and metabolic profile of each person to be taken 
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into account when treatment and follow-up options are being considered. The 
effectiveness of such an approach in reducing the prevalence of infection in the adult 
population demonstrated in this thesis, suggests that such a strategy could be 
successfully employed. While case finding and treatment has not been demonstrated 
to be effective in preventing transmission in children, or in eliminating the infection 
from a population, its ability to reduce the prevalence of infection in the population 
most at risk of hyper-infection may reduce the disease impact of this infection to 
negligible levels, while limiting any adverse metabolic effects. This approach could 
be seen as analogous to the “burden of disease” reduction strategies employed by the 
World Health Organization in the control of other STH infections, where the aim is 
not to eliminate the worm infection from a population, rather to reduce the burden of 
infection in those people most susceptible to the disease effects of the worm119. 
7.3 Further Research 
The findings in this thesis suggest several avenues for further research. Firstly, the 
prospective findings of an increase in the incidence of T2DM and worsening of 
glucose metabolism following treatment for S. stercoralis infection demand further 
investigation through larger multi-centre trials conducted over a larger time span. 
Randomized controlled trials in this area are difficult to conceive of as they would 
necessarily fall short of ethical approval. Cohort studies identifying children and 
teenagers with S. stercoralis infection, and then following their metabolic profile into 
adulthood could be of significant interest, both in determining the potential long-term 
effects of childhood helminth infection on metabolism, and in comparing the 
outcomes for treated individuals compared to those who are found to have persisting 
infection in adulthood. The success of a case finding and treatment strategy in 
controlling the infection in a paediatric population, and in reducing transmission of 
the infection would also be of great interest. 
A population of particular interest is pregnant women. Strongyloides infection in 
pregnancy presents unique challenges, as ivermectin is not currently licenced for use 
in pregnancy, and effective treatment is therefore not available until after delivery. 
Routine screening for strongyloides infection as a part of antenatal care is not 
universally adopted throughout northern Australia. Studies which examine the 
potential effect of ongoing infection on the rate of gestational diabetes are likely to be 
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of interest. Strongyloides also poses a significant potential risk to pregnant women 
through iatrogenic hyper-infection, and an ongoing danger to the babies of infected 
mothers through possible vertical and neonatal transmission. The development of 
protocols for dealing with the presence of strongyloides infection in pregnancy and 
the immediate post-partum period should be developed as a matter of priority120. 
Finally, laboratory investigations to isolate some of the candidate excretory/ secretory 
proteins produced by S. stercoralis infection, to determine the safety of their use in 
humans, and to determine their possible immuno-metabolic effects, could hold out the 
long-term prospect of identifying novel chemotherapeutic agents for the prevention 
and treatment of T2DM in susceptible populations. This thesis makes a contribution 
by beginning to unravel the relationship between one of the oldest infections known 
to man, and one of the most challenging illnesses to confront health services in the 
coming decades. 
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Appendix 1 Summary of Search 
Databases Searched: Medline: 1980 – November 2017, Embase: 1980 – November 
2017. 
 English language or foreign language articles with an English abstract were 
searched.  
 Only human studies were included.  
 All study designs or publication types (research articles including clinical 
trials, systematic reviews, review articles, editorials, letters, case reports) were 
included.  
 Includes conference abstracts in Embase.  
Summary of Search:  
The association between helminth infections (i.e. helminth, nematode, cestoda, 
trematode, soil transmitted helminths, hookworm, trichuris, ascaris, strongyloides 
including Strongyloides stercoralis, schistosoma, filariasis, onchocerca and 
opisthorchis) and metabolic diseases (i.e. metabolic disease, type 2 diabetes mellitus, 
insulin resistance, glucose intolerance, atherogenic index, atherosclerosis, vascular 
disease, HOMA-IR, resistin, adiponectin and leptin)  
The search strategy was devised using two main concepts: (1) ‘Helminth infections’ 
AND (2) ‘Metabolic disease’. The specific terms searched for each of these concepts 
are outlined in the ‘Summary of Search’ section above. Some of these search terms 
were kept broad such as ‘metabolic disease’ and ‘vascular disease’. All the search 
terms were majored to make them the main focus of the papers in order to minimise 
the number of irrelevant references retrieved. Both major thesaurus terms (located in 
the MeSH/Subject field of references) and text words were identified for each 
concept. With regard to ‘helminth infections’, the thesaurus term was exploded to 
retrieve narrower more specific infections such as ‘strongyloidiasis’. 768 references 
were retrieved using this search strategy and titles were manually scanned for 
relevancy. A total of 67 references were identified, and the abstracts were accessed. 
The references of review articles were in turn reviewed. This resulted in a total of 38 
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Appendix 2 Tables 
Appendix Table 1 Prevalence of Eosinophilia (≥0.5) and S. stercoralis (E-titre ≥0.4) by diabetes status 
Diabetes status Eosinophils measure 
S. stercoralis serology status (ELISA titre)   
Positive (% E-titre ≥0.4) Negative (% E-titre <0.4) Total 
n % n % N % 
Non-diabetic 45 39.1 70 60.9 115 100.0 
  Eosinophilia (≥0.5) 24 53.3 21 46.7 45 100.0 
  Non-eosinophilia (<0.5) 21 30.0 49 70.0 70 100.0 
                
Diabetic   26 21.0 98 79.0 124 100.0 
  Eosinophilia (≥0.5) 20 38.5 32 61.5 52 100.0 
  Non-eosinophilia (<0.5) 6 8.3 66 91.7 72 100.0 
                
Total   71 29.7 168 70.3 239 100.0 
  Eosinophilia (≥0.5) 44 45.4 53 54.6 97 100.0 
  Non-eosinophilia (<0.5) 27 19.0 115 81.0 142 100.0 
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Appendix Table 2 Accuracy of Eosinophilia (≥0.5) as a measure of S. stercoralis 
status determined by serology (E-titre ≥0.4) 
Parameters 
Non-diabetic 
(n=115) Diabetic (n=124) Total (n=239) 
  n (%) n (%) n (%) 
True negatives 49 (42.6) 66 (53.2) 115 (48.1) 
False positives 21 (18.3) 32 (25.8) 53 (22.2) 
True positives 24 (20.9) 20 (16.1) 44 (18.4) 
False negatives 21 (18.3) 6 (4.8) 27 (11.3) 
              
  (%) (95% CI) (%) (95% CI) (%) (95% CI) 
Sensitivity 
(53.3
) (37.9, 68.3) 
(76.9
) (56.4, 91) 
(62.0
) 
(49.7, 
73.2) 
Specificity 
(70.0
) (57.9, 80.4) 
(67.3
) 
(57.1, 
76.5) 
(68.5
) 
(60.8, 
75.4) 
Positive predictive 
value 
(53.3
) (37.9, 68.3) 
(38.5
) (25.3, 53) 
(45.4
) 
(35.2, 
55.8) 
Negative predictive 
value 
(70.0
) (57.9, 80.4) 
(91.7
) 
(82.7, 
96.9) 
(81.0
) 
(73.6, 
87.1) 
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Appendix Table 3 Regression analyses of sensitivity, specificity, positive predictive value 
and negative predictive value by diabetes status 
Analysis Diabetes status 
Unadjusted odds ratio   Adjusted odds ratio† 
n OR (95% CI)   n OR (95% CI) 
Analysis of sensitivity 71       66     
  Non-diabetic 45 1.00     41 1.00   
  Diabetic 26 2.92 (0.99, 8.62)   25 3.68 (1.05, 12.91)* 
                  
Analysis of specificity 168       157     
  Non-diabetic 70 1.00     66 1.00   
  Diabetic 98 0.88 (0.46, 1.72)   91 0.99 (0.47, 2.06) 
                  
Analysis of positive predictive 
value 97       95     
  Non-diabetic 45 1.00     43 1.00   
  Diabetic 52 0.55 (0.24, 1.23)   52 0.53 (0.20, 1.39) 
                  
Analysis of negative predictive 
value 142       128     
  Non-diabetic 70 1.00     64 1.00   
  Diabetic 72 4.71 (1.77, 12.56)*   64 5.50 (1.83, 16.56)* 
* p<0.05                 
† Adjusted for sex, age, BMI and past antibiotic treatment 
Eosinophilia (≥0.5) and S. stercoralis (E-titre ≥0.4) 
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